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ABSTRACT 
 
Erin R. Cernkovich 
Function and Activation of Signal Transducer and Activator of Transcription 3 (STAT3) in 
Adipose Tissue Formation and Metabolism 
(Under the direction of Joyce B. Harp) 
 
 Obesity is a significant medical and public heath concern due to its prevalence, 
associated co-morbidities, and economic impact.  Obesity ensues when adipocytes 
accommodate excess energy through enhanced triacylglycerol (TAG) storage, and when 
adipocytes increase in number via adipogenesis.  Signal Transducer and Activator of 
Transcription 3 (STAT3), a mitogenic signaling protein, is activated during the proliferative 
phases of adipogenesis.  We hypothesized therefore, that STAT3 plays a necessary role in 
adipogenesis.  This dissertation describes two independent projects that examined the 
function and activation of STAT3 in adipose tissue formation and adipocyte metabolism.   
 
 Using an adipocyte cell line, we determined that STAT3 activation during 
adipogenesis occurred indirectly through the synthesis of an autocrine/paracrine factor.  We 
identified the factor to be midkine, a pleiotrophic growth factor, and determined that the 
midkine-STAT3 signaling pathway plays a necessary role in adipogenesis.  This study 
supported the hypothesis that STAT3 is necessary for adipogenesis and prompted a 
subsequent study aimed to determine the physiological role of STAT3 in adipogenesis in 
animals.  In this study we used Cre-loxP DNA recombination to create mice with an 
adipocyte-specific disruption of the STAT3 gene (ASKO mice).  aP2-Cre driven 
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disappearance of STAT3 expression occurred on day 6 of adipogenesis, a time point when 
preadipocytes have already undergone conversion to adipocytes.  Thus, this knockout model 
examined the role of STAT3 in mature, but not differentiating adipocytes  ASKO mice 
weighed more than their littermate controls and had increased adipose tissue mass associated 
with adipocyte hypertrophy, but not adipocyte hyperplasia, hyperphagia, or reduced energy 
expenditure.  Leptin-induced lipolysis was impaired in ASKO adipocytes, which may 
partially explain the adipocyte hypertrophy.  Despite reduced adiponectin and increased liver 
TAG, ASKO mice did not develop impaired glucose tolerance or other obesity-related 
metabolic perturbations.   
 
 Overall, this work improved our understanding of preadipocyte proliferation, 
differentiation, and metabolism by establishing a necessary role for STAT3 and the 
midkine/STAT3 signaling pathway in these processes.  This work will help to direct efforts 
to identify potential adipose-tissue driven causes of obesity and to discover targets for the 
treatment of diseases such as obesity, hepatic steatosis, and insulin resistance.   
v 
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CHAPTER I 
INTRODUCTION 
 
A.  BACKGROUND 
 
 Obesity is a significant medical and public health concern due to its prevalence, 
associated co-morbidities, and economic impact (1).  Obesity ensues when energy intake 
chronically exceeds energy expenditure (2).  At the cellular level, white adipose tissue 
(WAT) expansion occurs in response to positive energy balance.  WAT expands when 
adipocytes accommodate excess energy through enhanced triacylglycerol (TAG) storage.  
WAT also expands when adipocytes increase in number.  It is postulated that adipocyte 
hyperplasia occurs when adipocytes reach a critical size threshold, during which signals are 
transmitted from adipocytes to preadipocytes to stimulate the formation of new adipocytes to 
store excess energy (3-5). 
   
 Many of the advances in our understanding of adipogenesis are based on studies in 
3T3-L1 cells.  3T3-L1 preadipocytes are fibroblast-like cells committed to the adipocyte 
lineage.   In culture, 3T3-L1 preadipocytes replicate until they form a confluent monolayer 
(6).  At confluence, cell-cell contact triggers growth arrest.  When induced with hormonal 
agents, often a cocktail of isobutylmethylxanthine, dexamethasone, and insulin (MDI), 
growth-arrested preadipocytes reenter the cell cycle and undergo 1-2 rounds of cell division 
known as mitotic clonal expansion (7).  Following mitotic clonal expansion, preadipocytes 
exit the cell cycle, commit to terminal differentiation, and begin to express adipocyte specific 
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genes (8).  Although much is known about the mechanisms of preadipocyte 
differentiation, less is known about preadipocyte proliferation.   
 
 The major transcriptional regulators of adipogenesis include proteins belonging to the 
CCAAT/enhancer binding protein (C/EBP) family and the peroxisome proliferator-activated 
receptor (PPAR)  superfamily (9-11).  A coordinated cascade involving the above mentioned 
factors typifies the differentiated phenotype.  Specifically, C/EBPβ and C/EBPδ induce 
C/EBPα (12) and PPARγ (13) expression, which in turn promote the terminally differentiated 
state (14).  Previous cell culture studies in our laboratory suggest that signal transducer and 
activator of transcription 3 (STAT3) is an important adipogenic transcription factor as well.  
STAT3 is abundantly expressed in preadipocytes and adipocytes (15), and highly activated 
and bound to DNA in proliferating preadipocytes and adipocytes (16).  In addition, inhibition 
of endogenous STAT3 expression with antisense morpholino oligonucleotides significantly 
decreases preadipocyte proliferation (16).  The specific function of STAT3 in preadipocyte 
proliferation and differentiation, however, is not yet known.    
  
 Cytokines and growth factors activate STAT3 by activating receptor and nonreceptor 
tyrosine kinases that phosphorylate STAT3 on a critical tyrosine residue (17).  Upon 
activation, STAT3 dimerizes with other STATs and translocates to the nucleus where it binds 
to specific DNA regulatory sequences to stimulate the transcription of target genes.  Previous 
cell culture studies in our laboratory report that STAT3 activation during adipogenesis is 
delayed.  The mechanism of delayed activation, however, is not yet known, but 
preliminary studies suggest that midkine, a heparin binding growth factor, is the  
3 
autocrine activator of STAT3. 
 
 STAT3 is also activated in adipocytes by leptin, interleukin-6 (IL-6), and ciliary 
neurotrophic factor (CNTF).  These cytokines have been shown to regulate body weight via 
anti-lipogenic and pro-lipolytic actions on adipocytes (18-32).  Because STAT3 is a 
downstream target of leptin, IL-6 and CNTF signaling, it has been hypothesized that STAT3 
mediates the effects of these cytokines.  The contribution of STAT3 to these aspects of 
body weight homeostasis, however, has yet to be determined.  
 
 
B.  SPECIFIC AIMS 
 
1.   Identify the differentiation-induced STAT3 activating factor and determine its role in 
preadipocyte proliferation and differentiation. 
2.   Using Cre-loxP DNA recombination, generate mice with an adipose-specific 
disruption of the STAT3 gene (ASKO mice). 
3.   Determine the functional role of STAT3 in adipocyte formation and body weight 
homeostasis using ASKO mice and primary preadipocytes isolated from ASKO mice. 
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CHAPTER II 
LITERATURE REVIEW 
 
A.  ADIPOGENESIS 
 
 Obesity is a significant medical and public health concern due to its prevalence, 
associated co-morbidities, and economic impact (1).  Obesity ensues when energy intake 
chronically exceeds energy expenditure (2).  At the cellular level, white adipose tissue 
(WAT) expansion occurs in response to positive energy balance.  WAT expands when 
adipocytes accommodate excess energy through enhanced triacylglycerol (TAG) storage.  
WAT also expands when adipocytes increase in number.  It is postulated that when 
adipocytes reach a critical size threshold, preadipocytes undergo adipogenesis (3-5). 
  
 Many of the advances in our understanding of adipogenesis are based on studies in 
embryonic derived 3T3-L1 cells.  3T3-L1 preadipocytes are a clonal subline of fibroblast-
like cells committed to the adipocyte lineage (6, 33).  When induced with hormonal agents, 
often a cocktail of isobutylmethylxanthine, dexamethasone, and insulin (MDI), this cell line 
can be differentiated into cells that biochemically and morphologically resemble mature 
adipocytes.  
 
1.  Inducers of Adipogenesis  
 The MDI protocol for the differentiation of 3T3-L1 preadipocytes was established in 
the late 1970s by Rubin et al.(34).  Rubin et al. stimulated 2-day postconfluent preadipocytes 
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with isobutylmethylxanthine (MIX), dexamethasone, and insulin.  MIX, a cAMP 
phosphodiesterase inhibitor, increases intracellular cAMP; dexamethasone, a synthetic 
glucocorticoid, activates the glucocorticoid receptor signaling pathway; and insulin, a 
mitogen, signals through the insulin-like growth factor-I (IGF-I) receptor.  cAMP and 
dexamethasone promote adipogenesis by regulating the expression of adipogenic 
transcription factors, inhibitors of adipogenesis, and adipocyte-specific genes.  The effects of 
insulin on differentiation have been shown to occur through activation of the IGF-I receptor 
and several distinct downstream signal transduction pathways, including the mitogen-
activated protein kinase (MAPK) cascade (35).  
 
2.  Necessary Events in Adipogenesis 
 Adipogenesis in vitro follows a well-characterized temporal sequence (Figure 2.1).  
3T3-L1 preadipocytes replicate in culture until they form a confluent monolayer.  At 
confluence, cell-cell contact triggers growth arrest in G0/G1 of the cell cycle.  Upon 
stimulation with MDI, postconfluent growth-arrested preadipocytes reenter the cell cycle and 
undergo 1-2 rounds of cell division known as mitotic clonal expansion.  Following mitotic 
clonal expansion, differentiating preadipocytes exit the cell cycle, arrest in G0/G1, commit to 
terminal differentiation, and begin to express adipocyte specific genes (8).  Proteins 
belonging to the CCAAT/enhancer binding protein (C/EBP) family and peroxisome 
proliferator-activated receptor γ (PPARγ) regulate the above-mentioned events.  
 
2.1  Growth Arrest at Confluence 
The first stage in the differentiation of adipocytes is growth arrest.  Growth arrest is
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Figure 2.1 – Necessary events in 3T3-L1 adipogenesis. 
Preadipocytes replicate until they form a confluent monolayer.  At confluence, cell cell 
contact triggers growth arrest.  When induced with hormonal agents, often a cocktail of 
isobutylmethylxanthine, dexamethasone, and insulin (MDI), growth arrested preadipocytes 
reenter the cell cycle and undergo 1-2 rounds of cell division known as mitotic clonal 
expansion.   
Mitotic clonal expansion is characterized by an increase in the expression of the adipogenic 
transcription factors C/EBP β and δ and the tyrosine phosphorylation and activation of 
STAT3.  Following mitotic clonal expansion, preadipocytes exit the cell cycle, commit to 
terminal differentiation and begin to express adipocyte specific genes. 
PPARγ and C/EBPα expression coincides with the end of mitotic clonal expansion and 
induction of the second permanent period of growth arrest.  PPARγ and C/EBPα induce 
expression of each other and act synergistically to promote differentiation and induce 
expression of adipocyte specific genes.   
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achieved following contact inhibition and is accompanied by changes in the pattern of gene 
expression; growth arrested preadipocytes express early, differentiation-specific markers.  
Pairault et al. have determined that growth arrest at confluence is necessary for preadipocyte 
differentiation (36). 
 
2.2  Mitotic Clonal Expansion 
 Mitotic clonal expansion refers to the three-day period during which growth arrested 
preadipocytes synchronously enter the S phase of the cell cycle and undergo several rounds 
of cell division in response to MDI stimulation.  Being a period of cellular proliferation, 
mitotic clonal expansion is characterized by the activation of cyclin dependent kinase 2 by 
cyclins E and A, the down regulation of the cyclin dependent kinase inhibitor p27, and the 
incorporation of [3H] thymidine into DNA (37).  Mitotic clonal expansion is also 
characterized by a transient increase in the expression of the transcription factors C/EBPβ 
(38) and C/EBPδ (38) as well as the tyrosine phosphorylation and activation of the 
transcription factor signal transducer and activator of transcription 3 (STAT3) (16).   
 
 Several groups have established that mitotic clonal expansion is required for 
progression through the differentiation program.  Mitotic clonal expansion and differentiation 
are blocked by an inhibitor of DNA polymerase α (39).  Consistent with these results, mitotic 
clonal expansion and differentiation are also blocked by blocking the down regulation of a 
cyclin dependent kinase inhibitor (40), and by blocking S phase entry with a cyclin 
dependent kinase inhibitor (37).   The requirement of cell division for differentiation has 
been controversial, however.  Some evidence suggests that primary preadipocytes can 
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 differentiate in culture without undergoing clonal expansion (41). 
 
2.3  Commitment to Terminal Differentiation 
 Following mitotic clonal expansion, preadipocytes exit the cell cycle, arrest in G0/G1, 
commit to terminal differentiation, and begin to express adipocyte-specific genes, including 
proteins required for lipogenesis and lipolysis (8).  During this terminal phase, preadipocytes 
also alter the expression of cytoskeletal and extracellular matrix components and undergo 
dramatic morphological changes required for acquisition of the adipocyte phenotype, 
including conversion from a fibroblastic to a spherical shape with lipid-laden droplets.   
  
 This second period of growth arrest is permanent and coincides with a decline in 
C/EBPβ and C/EBPδ expression, and the onset of C/EBPα and PPARγ expression.  Like 
growth arrest at confluence, growth arrest after mitotic clonal expansion is necessary for 
terminal differentiation (42). 
  
3.  Adipogenic Transcription Factors 
 The major transcriptional regulators of adipogenesis include proteins belonging to the 
C/EBP family and the PPAR superfamily (9-11).  A coordinated cascade involving the above 
mentioned factors typifies the differentiated phenotype.  Specifically, C/EBPβ and C/EBPδ 
induce C/EBPα and PPARγ expression, which in turn promote the terminally differentiated 
state.  Adipocyte determination and differentiation-dependent factor-1 (ADD1/SREBP-1), 
cAMP response element binding protein (CREB), and signal transducers and activators of 
transcription (STATs) have also been implicated in the differentiation program. 
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3.1  CCAAT/Enhancer-Binding Proteins (C/EBPs) 
 The first transcription factors found to participate in adipogenesis were members of 
the C/EBP family.  The C/EBP family has six members:  -α, -β, -γ, -δ, -ε, and –ζ.  C/EBPα, 
C/EBPβ, c/EBPδ, and C/EBPζ are expressed in adipose tissue and adipocyte cell lines (43). 
 
3.1.1  C/EBPβ and C/EBPδ 
 Two to four hours after induction of differentiation, proliferating preadipocytes 
express C/EBPβ and C/EBPδ, with MIX inducing the expression of C/EBPβ and 
dexamethasone inducing C/EBPδ expression (38).  Although C/EBPβ and C/EBPδ are 
expressed soon after induction of differentiation, they are unable to bind DNA, and thus 
cannot function as transcriptional activators  (7).  Tang et al. (7) report that acquisition of 
DNA-binding activity occurs 10-12 hours later as postconfluent growth-arrested 
preadipocytes reenter the cell cycle and begin mitotic clonal expansion.  Upon acquiring 
DNA binding activity, C/EBPβ and C/EBPδ synergistically promote the expression of 
PPARγ (13) and C/EBPα (12).  Gene expression is mediated by C/EBP regulatory elements 
present in the promoters of the PPARγ and C/EBPα genes (44, 45). 
  
 Gain and loss of function studies define a role for C/EBPβ and C/EBPδ in 
adipogenesis.  Several groups confirm that C/EBPβ is necessary for mitotic clonal expansion 
and differentiation, while C/EBPδ plays a relatively minor role.  Specifically, ectopic 
expression of C/EBPβ is sufficient to induce the differentiation of preadipocytes in the 
absence of hormonal inducers (12), while ectopic expression of C/EBPδ accelerates 
adipogenesis, but only in the presence of hormonal inducers.  Additionally, mouse embryonic 
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fibroblasts (MEFs) lacking C/EBPδ show slight reductions in adipogenic potential (46), 
while MEFs from C/EBPβ knockout mice neither undergo mitotic clonal expansion nor 
differentiate into adipocytes (47).   
  
 In vivo results from mice lacking C/EBPβ and/or C/EBPδ are more ambiguous.  
These data suggest that C/EBPβ and C/EBPδ have a synergistic role in adipocyte 
differentiation.  Specifically, mice lacking either C/EBPβ or C/EBPδ have normal WAT.  
Eighty-five percent of mice lacking both C/EBPβ and C/EBPδ, however, die during the 
prenatal period.  The remaining 15% of these mice do not accumulate lipid droplets in their 
brown adipose tissue (BAT), and their epididymal fat pad weight is significantly reduced 
(46).   
 
3.1.2  C/EBPα 
 C/EBPα is expressed late in the differentiation program.  Its expression coincides 
with the end of mitotic clonal expansion and induction of the second, permanent period of 
growth arrest.  C/EBPα expression remains elevated for the remainder of the differentiation 
program and throughout the life of the mature adipocyte.  In view of its pattern of expression, 
an important role for C/EBPα in adipogenesis was suggested.   This hypothesis was 
supported by the finding that, when ectopically expressed, C/EBPα stimulates the expression 
of gadd45 and p21, thus inducing growth arrest and terminating mitotic clonal expansion 
(48).  It was further supported by studies showing that C/EBPα regulates the expression of 
adipocyte-specific genes including FABP2/aP2, GLUT-4, phosphoenolpyruvate 
carboxykinase (PEPCK), and insulin receptor (49-51).   
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Given its role in the acquisition of the growth arrested state and the terminally 
differentiated phenotype, it is not surprising that several laboratories have concluded that 
C/EBPα is critical for the adipogenic program.  The involvement of C/EBPα in adipogenesis 
is strongly supported by in vitro and in vivo studies.  In the absence of hormonal stimulants, 
constitutive expression of C/EBPα is sufficient for adipogenesis (52). Furthermore, 
diminution of endogenous C/EBPα expression by antisense oligonucleotides inhibits 
adipogenesis (53).  Finally, MEFs lacking C/EBPα have reduced adipogenic potential (54), 
and mice with a homozygous deletion in C/EBPα have dramatically reduced fat 
accumulation in WAT (55).   
 
3.2  Peroxisome Proliferator-Activated Receptors (PPARs) 
  Adipogenesis also requires the activity of PPARs, members of the nuclear receptor 
superfamily of ligand-activated transcription factors.  The PPAR family has three members:  
-α, -γ, and -δ.  Adipose tissue and adipocyte cell lines express high levels of PPARγ.  PPARγ 
is expressed as two isoforms, PPARγ1 and PPARγ2.  While many tissues express PPARγ1, 
PPARγ2 is expressed almost exclusively in white and brown adipose tissue (56).   
 
3.2.1  PPARγ 
 PPARγ is expressed late in the differentiation program.  Similar to C/EBPα, its 
expression coincides with the end of mitotic clonal expansion and induction of growth arrest.  
PPARγ expression also remains elevated for the remainder of the differentiation program and 
throughout the life of the mature adipocyte.  This expression pattern suggested an important 
role for PPARγ in adipogenesis.  This hypothesis was supported by the finding that PPARγ 
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stimulates the expression of the cyclin-dependent kinase inhibitors p18 and p21, thus 
inducing growth arrest and terminating mitotic clonal expansion (57).  It was further 
supported by studies showing that PPARγ promotes differentiation by increasing the 
expression of adipocyte-specific genes that confer the adipocyte phenotype, including 
FABP2/aP2, lipoprotein lipase (LPL), acyl-CoA synthase (ACS), fatty acid synthase (FAS), 
and PEPCK (56, 58, 59) 
  
 Gain and loss of function studies further demonstrate the sufficiency of PPARγ for 
adipogenesis.  Studies conducted in ES cells lacking PPARγ (60) and MEFs deficient in 
PPARγ show that PPARγ is necessary for in vitro differentiation.  Additional studies confirm 
that PPARγ is sufficient for adipogenesis as well.  Specifically, ectopic expression of PPARγ 
in non-adipogenic fibroblasts triggers the adipogenic program (61), and PPARγ ligands can 
substitute for adipogenic hormones during the differentiation of preadipocytes (62). 
 
 Loss of function experiments in vivo however proved difficult because mice with a 
homozygous deletion in PPARγ die in utero (63).  To circumvent this difficulty, Rosen et al. 
(60) studied chimeric mice, made by mixing wild-type and PPARγ-/- embryonic stem (ES) 
cells.  The adipose tissue from these mice developes normally.  However, the tissue is 
derived predominately from wild-type cells, not PPARγ-/- cells.  The relative contribution of 
each ES cell genotype provides evidence that PPARγ is required for the differentiation of 
adipose tissue in vivo.  Studies performed in mice with an adipose specific deletion in PPARγ 
confirm this conclusion (64).  These mice display progressive lipodystrophy and develop 
associated metabolic perturbations, including liver and WAT insulin resistance. 
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 In the above mentioned mouse models, both PPARγ1 and PPARγ2 transcripts were 
inactivated.  Because PPARγ2 is expressed almost exclusively in white and brown adipose 
tissue (56), it has been suggested that PPARγ2 may be more adipogenic than PPARγ1.  
Recently Zhang et al. (65) reported that a PPARγ2 deficiency impairs the development of 
adipose tissue.  They conclude that, while both PPARγ1 and PPARγ2 can drive adipose 
tissue development, PPARγ2 plays the dominant role.  Specifically, PPARγ2-/- mice exhibit 
an overall reduction in WAT.  Furthermore, consistent with in vivo data, PPARγ2-/- MEFs 
show a dramatically reduced capacity for adipogenesis compared to wild-type MEFs.  
 
 Because C/EBPα and PPARγ act synergistically to promote adipocyte differentiation, 
important questions arose about the relative roles of PPARγ and C/EBPα in adipogenesis:  do 
they operate independently in separate, parallel pathways of differentiation, or does a single 
pathway exist?  Rosen et al. (66) demonstrated that C/EBPα and PPARγ participate in a 
single pathway with PPARγ being the primary regulator of adipogenesis.  Specifically, MEFs 
from mice lacking C/EBPα fail to express PPARγ and are unable to differentiate into 
adipocytes (54).  Similarly, MEFs from mice lacking PPARγ express greatly reduced levels 
of C/EBPα and are unable to differentiate into adipocytes (63).  Adding PPARγ back to 
C/EBPα-/- fibroblasts, however restores their capacity to accumulate lipid and activate 
markers of adipogenesis (54).  C/EBPα, however, can not rescue adipogenesis in  PPAR-/- 
fibroblasts (66). 
 
B.  SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION (STATs) 
 STAT1, -2, -3, -4, -5A, -5B, and -6 comprise a group of cytosolic latent transcription 
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factors that participate in normal cellular events, including differentiation, proliferation, cell 
survival, and apoptosis, following activation by cytokines, peptides, and growth factors (17).  
 
1.  Structural Features of STATs 
 STATs share several conserved domains critical for STAT functions (67):  a coiled-
coil domain, a DNA binding domain, an SH2 domain, a linker domain, a critical tyrosine 
residue, and a transcriptional activation domain  The coiled-coil domain contains four helical 
coils which provide protein-protein interaction sites.  The SH2 domain is required for the 
recruitment of STATs to phosphorylated receptors and for the SH2-phosphotyrosine 
interactions between monomeric STATs (67).  The linker domain precedes the SH2 domain 
and links it to the DNA binding domain.  The conserved tyrosine residue exists near the 
carboxy-terminus of all STAT proteins.  STATs are activated through phosphorylation of this 
tyrosine residue.  The carboxy-terminus also contains the transcriptional activation domain.  
Figure 2.2 shows these conserved domains of STAT proteins. 
 
2.  Mechanisms of Activation 
 STAT proteins are latent in the cytoplasm and become activated via tyrosine 
phosphorylation when extracellular proteins bind to their corresponding cell surface receptors 
(Figure 2.3).  That is, ligand binding triggers receptor dimerization.  Dimerized receptors 
subsequently activate various receptor and non-receptor tyrosine kinases (NRTK) that 
phosphorylate and activate STAT proteins.  Tyrosine phosphorylated STATs then homo- or 
heterodimerize through association between the SH2 domain of one STAT monomer and 
phosphotyrosine of another STAT monomer.  Specifically, STATs 5A and 5B interact as  
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Figure 2.2 – Conserved domains of the STAT family. 
The seven mammalian STAT proteins share six highly conserved domains, a coiled-coil 
domain, a DNA binding domain, a linker domain, an SH2 domain, a critical tyrosine residue, 
and a transcriptional activation domain.   
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heterodimers, while STATs 1, 3, 4, and 6 form homodimers (17).   STAT1 also forms 
heterodimers with both STAT2 and STAT3 (17).  Finally, activated STAT dimers translocate 
to the nucleus where they bind specific DNA regulatory sequences to stimulate the 
transcription of target genes.   
 
 Over 40 ligands have been shown to activate STAT proteins.  Growth factors 
including epidermal growth factor (EGF), platelet derived growth factor (PDGF), colony 
stimulating factor-1 (CSF-1), and hepatocyte growth factor (HGF) (68-71), can activate 
STATs.  Because growth factor receptors possess intrinsic tyrosine kinase activity, they can 
directly phosphorylate and activate STAT proteins following ligand binding.  Activated 
growth factor receptors can also recruit NRTKs, including Src, Syk, and Abl, to 
phosphorylate and active STATs (68).   
 
 Cytokines can also activate STAT proteins (72).  Cytokine receptors, however, do not 
have intrinsic kinase activity.  Consequently, receptor associated cytoplasmic proteins from 
the Janus kinase (Jak) family, including Jak1, Jak2, Jak3, and Tyk4, provide the required 
tyrosine kinase activity (73).  Upon ligand binding, these proteins bind to intracellular 
domains on the cytokine receptor and catalyze ligand-induced phosphorylation of themselves 
and of intracellular tyrosine residues on the cytokine receptor.   These phosphorylated 
tyrosines provide docking sites for STATs.  STAT proteins are recruited to the 
phosphorylated tyrosine, whereupon they are tyrosine phosphorylated by Jaks. 
 
 G-protein-coupled receptors, including receptors for angiotensin II (74) and serotonin  
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Figure 2.3 – Mechanisms of STAT activation 
STATs become tyrosine phosphorylated by four different mechanisms:  (1) Cytokine 
mediated activation by Jaks, (2) Growth factor mediated activation by receptor tyrosine 
kinases, (3) growth factor mediated activation by non-receptor tyrosine kinases (NRTK), and 
(4) G-protein mediated activation by Jaks and NRTK.  Tyrosine phosphorylated STATs form 
homo- or heterodimers, and then translocate to the nucleus where they bind target sequences. 
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(75), have been shown to activate STATs as well (72).  It has been proposed that STATs are 
activated by both Jaks and NRTKs associated with G-protein-coupled receptors (74, 76).  
 
3.  Functions of STATs 
 The physiological role of each STAT was examined through the study of knockout 
mice (Table 2.1).  Targeted disruption of STAT1 and STAT2 revealed that these STATs 
mediate the effects of interferons.  Specifically, STAT1 deficient mice are unable to respond 
to type I and type II interferons and are subsequently susceptible to bacterial and viral 
pathogens (77, 78).  Furthermore, STAT2 knockout mice are unresponsive to type I 
interferons and thus sensitive to infection as well (79).  IL-12-mediated functions, including 
cellular proliferation and T helper 1 cell differentiation, are impaired in STAT4 knockout 
mice (80, 81).  STAT6 knockout mice have defects in IL-4 mediated functions, including T-
cell proliferation and T helper 2 cell development (82-84).  STAT4 and STAT6, therefore, 
are essential for mediating the effects of IL-12 and IL-4 respectively.  STAT5A knockout 
females have defects in breast tissue development (85).  STAT5B knockout males grow 
slowly, weigh significantly less than control littermates, and exhibit female patterns of liver 
gene expression (86, 87).  STAT5B, therefore, is required for physiological responses to 
growth hormone while STAT5A is required for physiological responses to prolactin (87).  
 
STAT3 is indispensable during early embryogenesis.  Consequently, targeted 
disruption of the STAT3 gene leads to early embryonic lethality; Takeda et al. (88) report 
that STAT3 deficient embryos show a rapid degeneration between embryonic days 6.5 and 
7.5.  The cause of lethality has yet to be determined.  With the generation of the Cre-loxP  
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Target Gene Phenotype of Null Mice Reference 
STAT1 Impaired responses to type I and type II interferons (77, 78) 
STAT2 Impaired responses to type I interferons (79) 
STAT3 Embryonic lethality (88) 
STAT4 Loss of IL-12 mediated functions (80, 81) 
STAT5A Impaired breast development owing to loss of prolactin 
responsiveness 
(85, 87) 
STAT5B Impaired growth owing to loss of growth hormone 
responsiveness 
(86, 87) 
STAT6 Loss of IL-4 mediated functions (82-84) 
 
Table 2.1 – Role of STAT proteins as revealed by gene targeting in mice 
 
 
 
 
 
 
 
Target Tissue Phenotype of Tissue-Specific STAT3 Null Mice Reference 
β cells/Hypothalamus Obese, hyperphagic, hyperglycemic, 
hyperinsulinemic 
(89) 
Central Nervous System Obese, hyperphagic, hyperleptinemic, diabetic, 
infertile 
(90) 
Liver Obese, insulin resistant (91) 
Macrophages/Neutrophils Enhanced inflammatory responses (92) 
Mammary glands Impaired apoptosis (93) 
POMC Neurons Mildly obese, hyperphagic (94) 
T lymphocytes Impaired IL-6 induced proliferation (95) 
 
Table 2.2 - Tissue-specific roles of STAT3 as revealed by conditional gene targeting in 
mice 
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DNA recombination system (96), it has become possible to generate tissue-specific STAT3-
deficient mice (Table 2.2).  Analysis of these mice reveals an essential role for STAT3 in 
body weight and energy homeostasis.  Studies in mice with a neural-specific disruption in 
STAT3 demonstrate that STAT3 mediates most, if not all, hypothalamic leptin function (90).  
The phenotype of these mice resembles that of leptin deficient mice; mutant mice are 
hyperleptinemic, leptin resistant, obese, diabetic, and infertile.  Mice with a β 
cell/hypothalamic defect in STAT3 (89) and mice with a liver-specific defect in STAT3 (91) 
display similar phenotypes.  Through the study of these mice, Cui et al. (89) conclude that β-
cell/hypothalamic STAT3 plays a critical role in the control of food intake, body weight, 
insulin sensitivity, and leptin sensitivity, while Inoue et al. conclude that liver STAT3 plays 
an essential role in normal glucose homeostasis by regulating the expression of 
gluconeogenic genes (91).  Analyses of other tissue-specific STAT3 deficient mice elucidate 
essential roles for STAT3 in cytokine mediated biological functions and the promotion of 
cell proliferation through the prevention of apoptosis (92, 93, 95). 
 
 4.  STATs Effects on Cell Proliferation 
 Recent discoveries underscore the importance of STAT proteins in cell proliferation.   
Fukuda et al. (97) established that STATs promote cell proliferation through the upregulation 
of genes encoding cell cycle regulators and apoptosis inhibitors.  Specifically, they report 
that STAT3 plays a key role in the G1 to S phase cell-cycle transition through the 
upregulation of the cyclin dependent kinase (CDK) activators cyclin D2, cyclin D3, cyclin A, 
and cdc25A, and the concomitant down regulation of the CDK inhibitors p21 and p27 (97).  
Their conclusions are supported by studies demonstrating that dominant negative forms of 
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STAT3 inhibit the induction cyclin D, cyclin A, and cdc25A, and consequently inhibit entry 
into S phase of the cell cycle (97).  It is further supported by studies showing that cyclin D 
and the anti-apoptotic proteins Bcl-xL and Mcl-1 are STAT3 target gene (98-100).    
 
 In addition to the fundamental role of STATs in normal cell proliferation, 
accumulating evidence is defining a role for aberrant STAT signaling in oncogenesis as well 
(101).  Constitutively active STAT3 and STAT5 has been observed in a variety of human 
cancer cell lines and primary tumors, including blood malignancies (leukemia, lymphoma, 
multiple myeloma), and solid neoplasias (head and neck, brain, breast, lung, pancreas, 
prostate cancers) (101-105).  Constitutively active STAT3 and STAT5 have also been shown 
to possess transforming properties and to be strongly associated with tumor development and 
progression (101).  Several studies suggest that STAT3 and STAT5 participate in 
oncogenesis through the upregulation of genes encoding apoptosis inhibitors, and cell cycle 
regulators, including Bcl-xL and cyclin D respectively (98, 106).   
 
5.  STATs in Adipogenesis 
 STATs are abundantly expressed in cultured and native preadipocytes and adipocytes  
(15).  The expression of STAT1, STAT5A, and STAT5B increases significantly after the 
induction of differentiation, STAT3 levels increase slightly, while STAT6 expression does 
not change.  Expression of STATs 1, 5A, and 5B is regulated by PPARγ, suggesting a role 
for these STATs in the terminal phases of adipogenesis (107).  Expression of STATs 3 and 6, 
however, is regulated upstream the C/EBP family of transcription factors, suggesting a role 
for these STATs in the early phases of adipogenesis (107).   
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 Deng et al.(16) suggest a regulatory role for STAT3 during the proliferative phases of 
adipogenesis.  They report that STAT3 is tyrosine phosphorylated and bound to DNA as 
3T3-L1 cells proliferate and become confluent, as well as during mitotic clonal expansion 
when postconfluent growth-arrested preadipocytes undergo 1-2 rounds of cell division.  
STAT3 is not tyrosine phosphorylated, however, in growth arrested postconfluent 
preadipocytes or differentiating adipocytes.  This pattern of activation is specific for STAT3 
and does not occur for STAT1, STAT5A, STAT5B, or STAT6.  To elucidate a potential role 
for STAT3 during the proliferative phases of adipogenesis, Deng et al. blocked STAT3 
expression by antisense morpholino oligonucleotides.  They repot that diminution of 
endogenous STAT3 expression significantly decreases preconfluent preadipocyte 
proliferation.  The specific function of STAT3 in preadipocyte proliferation and 
differentiation, however, is not yet known.   
 
C.  STAT ACTIVATING FACTORS   
 STATs 2, 4, and 6 are activated by a small number of ligands.  STATs 1 and 5,  
however, are activated by means of a number of ligands.  STAT3 is also activated by several 
ligands including leptin, IL-6 family cytokines, and midkine.    
 
1.  Leptin 
 Leptin, the product of the ob gene, is a 16 kDa peptide hormone produced and  
secreted by adipocytes in proportion to adipose mass (108).  Leptin regulates food intake, 
energy expenditure, and body weight via central and peripheral actions.  The profound 
importance of leptin is demonstrated by mice with a homozygous mutation in the ob gene 
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(ob/ob) (109) or in its receptor (db/db) (110).  These mice develop massive obesity, 
hyperglycemia, hyperinsulinemia, and display reduced fertility and a reduced basal metabolic 
rate. 
 
1.1  Leptin Signaling 
 Leptin’s effects are mediated via its interaction with the leptin receptor (Ob-R).  Ob-R 
belongs to the class I cytokine receptor family and is produced in several alternatively spliced 
forms designated Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re, and Ob-Rf (110).  All five isoforms 
share a common extracellular domain and transmembrane domain.  The intracellular domain 
is characteristic for each isoform (110).  Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf have a short 
intracellular domain and are thought to play a role in the clearance of leptin from circulation 
(111), and in the transport of leptin to the brain (112).  Ob-Re lacks an intracellular domain 
and is believed to encode a soluble receptor (110).  Ob-Rb has a long intracellular domain 
and mediates most of leptin signaling (113).  
  
 Effects of leptin are further mediated via Ob-R activation of the Jak/STAT pathway  
(114); activation of alternative pathways, including the MAPK pathway, the PI3K pathway, 
and the AMPK pathway have also been reported (115). 
 
Upon leptin binding to the Ob-R, the Jak/STAT signaling cascade is initiated.  
Because the Ob-R does not have intrinsic kinase activity, the required tyrosine kinase activity 
is provided by receptor associated cytoplasmic proteins from the Jak family (116).  
Specifically, Jaks bind to intracellular domains on the Ob-R and catalyze ligand-induced 
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phosphorylation of themselves and of intracellular tyrosine residues on the Ob-R.  These 
phosphorylated tyrosines provide docking sites for STATs.  STAT proteins are recruited to 
these phosphorylated tyrosines, whereupon they are tyrosine phosphorylated by Jaks.  The 
activated STATs dimerize, translocate to the nucleus, and stimulate gene transcription.  
Leptin receptor binding activation of STAT1, 3, 5, and 6, has been described (115). 
  
 Originally, it was thought that the hypothalamus was the only tissue expressing the 
long form of the leptin receptor.  Recent evidence, however, confirmed that peripheral 
organs, including WAT, express the functional Ob-Rb as well (18, 117, 118).  Recent studies 
performed in vitro and in vivo further demonstrate that adipocyte Ob-Rb can activate the 
Jak/STAT pathway.  Specifically, incubation of 3T3-L1 adipocytes with recombinant leptin 
activates STAT3 (119).  Furthermore, intraperitoneal leptin administration to wild-type and 
ob/ob mice causes prompt activation and nuclear translocation of STAT1 and 3 in WAT 
(119, 120).  Kim et al. (119) confirm that this effect is mediated by the long form of the 
receptor; leptin injection in db/db mice does not result in STAT3 tyrosine phosphorylation.  
They further demonstrate that leptin directly activates STAT3 in WAT; 
intracerebroventricular administration of leptin does not result in adipocyte STAT3 tyrosine 
phosphorylation.    
 
1.2  Metabolic Effects  of Leptin in WAT 
Leptin’s metabolic effects are exerted at the level of the central nervous system, via 
Ob-Rb interaction in regions of the hypothalamus that control feeding behavior and hunger, 
body temperature and energy expenditure (121).  The metabolic effects of leptin are not due 
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solely to actions via the central nervous system however.  Several lines of evidence support 
direct peripheral effects of leptin as well.  For example, the presence of the Ob-Rb on 
adipocytes, and the adipose reducing effects of leptin beyond that that can be accounted for 
by a reduction in food intake alone (122), suggest that leptin might have direct 
autocrine/paracrine effects on adipocytes (19).  It is now clear from in vivo and ex vivo 
studies that leptin stimulates lipolysis in adipocytes (Section 1.2.1) (18-23).  Recent in vitro 
and in vivo studies also confirm that leptin promotes adipocyte fatty acid oxidation and 
inhibits lipogenesis (Section 1.2.2) (23-25).  Because STAT3 is a downstream target of 
leptin, STAT3 likely mediates the weight reducing effects of this cytokine on adipocytes.  
The contribution of STAT3 to these aspects of body weight homeostasis, however, has yet to 
be determined.     
 
Given the fat depleting autocrine/paracrine actions of leptin, it is surprising that diet-
induced obese (DIO) rodents undergo adipocyte hypertrophy despite hyperleptinemia within 
the fat-depleting range (123).  These findings prompted Wang et al. (123) to determine if 
adipocyte leptin resistance contributes to the pathogenesis of obesity (123).  In these studies, 
Wang et al. conclude that a leptinergic blockade, as demonstrated by a decrease in Ob-Rb 
expression, a decrease in STAT3 tyrosine phosphorylation, and an increase in suppressor of 
cytokine signaling-3 (SOCS3) expression, protects DIO rodents from leptin’s fat depleting 
autocrine/paracrine actions.  They also conclude that fat storage in adipocytes requires 
inactivation of leptin's autocrine/paracrine activities.   Specifically, by restoring Ob-Rb 
expression, Ob-Rb activation of the Jak/STAT signaling pathway, and the downstream anti-
lipogenic, and pro-lipolytic and -oxidative actions of leptin, transgenic mice that  
26 
 
 
 
 
Figure 2.4 – Metabolic effects of leptin in white adipose tissue                              
Leptin, via Ob-Rb activation of the Jak/STAT pathway, causes a down regulation of genes 
encoding lipogenic enzymes including ACC, FAS, and DGAT.  The down regulation of ACC 
results in a decrease in malonyl-CoA content and a subsequent increase in fatty acid 
oxidation by disinhibition of CPT1.       
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constitutively express Ob-Rb on adipocytes, remain slender on a high fat diet that causes 
obesity in wild-type controls.  Wang et al. (123) confirm that the slender phenotype is a 
consequence of increased oxidation of fatty acids within adipocytes, coupled with a reduction 
in lipogenesis.  Specifically, they report increased expression at the mRNA level of carnitine 
palmitoyltransferase-1 (CPT-1).  Furthermore, consistent with a reduction in lipogenesis, 
they report decreased expression of lipogenic enzymes, including acetyl-CoA carboxylase-1 
(ACC-1), diacylglycerol acyltransferase-1 (DGAT-1), diacylglycerol acyltransferase-2 
(DGAT-2), and glycerol-3-phosphate acyltransferase-1 (GPAT-1). 
 
1.2.1  Leptin Induced Lipolysis 
 Both in vivo and ex vivo studies confirm that leptin stimulates lipolysis in adipocytes.  
Specifically, leptin treatment in vivo dramatically reduces WAT triglyceride stores (19, 20).  
Additionally, in both ob/ob mice and lean mice, leptin increases glycerol release in a time- 
and dose-dependent manner (18, 21). Leptin-induced glycerol release, however, is 
unaccompanied by the parallel release of free fatty acids induced by other lipolytic hormones 
(23).   
 In contrast to ob/ob mice and lean mice, leptin’s lipolytic effects are absent in fat pads 
from db/db mice and fa/fa rats.  For example, in animal models lacking the functional Ob-Rb, 
injections of leptin have no significant effect on lipolytic activity (22).  Ex vivo studies 
performed by Siegrist-Kaiser et al., (18), show similar results.  Leptin stimulates basal 
lipolysis in white fat pads ex vivo in a time- and dose-dependent manner.  This effect is 
absent in fat pads from fa/fa rats, thus confirming the requirement of a functional Ob-Rb.  
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1.2.2  Leptin and Fatty Acid Oxidation/Lipogenesis 
 In vitro and in vivo studies confirm that leptin stimulates fatty acid oxidation and 
inhibits lipogenesis in adipocytes.  In 30A5 preadipocytes, leptin represses ACC gene 
expression and activity, and inhibits the subsequent processes of fatty acid synthesis and 
TAG synthesis (24).  Zhou et al. (25) observed an increase in fatty acid oxidation and a 
reduction in lipogenesis in adenovirus-induced hyperleptinemic rats (25).  Decreases in ACC 
expression and activity explained the observed changes in this mouse model; 
phosphorylation and inhibition of ACC reduced the capacity of adipocytes to form new fat 
and increased fatty acid oxidation by reducing malonyl CoA levels and thereby disinhibiting 
CPT-1.  Orci et al. (23) further report that in vivo adenovirus induced hyperleptinemia 
decreases the expression of enzymes of fatty acid synthesis, including fatty acid synthase 
(FAS), and increases the expression of enzymes of fatty acid oxidation, including CPT-1 and 
acyl-CoA oxidase (ACO).  
 
2.  IL-6-Type Cytokines 
 The interleukin-6 (IL-6) family of cytokines is a family of structurally and  
functionally related proteins, including IL-6, IL-11, leukemia inhibitory factor (LIF), 
oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), and 
cardiotrophin-like cytokine (CLC).  These cytokines activate target genes involved in 
proliferation, differentiation, and apoptosis (124).  Two of the IL-6 family members, IL-6 
and CNTF, have metabolic actions as well; both IL-6 and CNTF suppress appetite and 
induce weight loss.  It was recently suggested that the anti-obesity effects of IL-6 and CNTF 
are due in part to direct autocrine/paracrine actions on adipocytes.   
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2.1  IL-6-and CNTF Signaling 
 IL-6 and CNTF exert their metabolic actions through binding, sequential assembly, 
and activation of a multi-subunit receptor complex composed of a ligand-specific α subunit 
and a signal transducing subunit.  The binding of IL-6 and CNTF to their respective α 
receptor triggers the association and dimerization of the signal transducing subunit, leading 
to activation of the Jak/STAT pathway.  Specifically, the binding of IL-6 to the IL-6Rα 
triggers the subsequent association and homodimerization of gp130 (125), while the binding 
of CNTF to the CNTFRα triggers the subsequent association and heterodimerization of the 
gp130 and LIFR (126).   
 
2.2 Metabolic Effects of IL-6 in WAT 
 IL-6 is released from immune cells during inflammation whereupon it elicits pro- 
inflammatory effects including induction of the acute-phase response, and proliferation and 
differentiation of B- and T-lymphocytes (127).  In the absence of inflammation, a large 
proportion of circulating IL-6 is derived from adipose tissue (128).  Similarly to leptin, IL-6 
levels in the serum correlate positively with BMI, suggesting an important role for this 
cytokine in body weight homeostasis.  To investigate the role of IL-6 in the regulation of 
body weight, Wallenius et al. (129) created IL-6 knockout mice.  These mice develop 
mature-onset obesity that is partially reversed by IL-6 replacement.  The obesity related 
metabolic perturbations that accompany mature-onset obesity are also partially reversed by 
intraperitoneal injection of IL-6 (129).  It was recently postulated by Wallenius et al. (130) 
that IL-6 functions as a lipostatic protein, similarly to leptin, to cause weight loss.  This 
hypothesis is supported by the finding that the IL-6 receptor complex is distributed in regions 
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of the hypothalamus involved in the regulation of food intake and body weight (131, 132).  It 
is further supported by studies showing that centrally administered IL-6 decreases body fat 
mass by increasing energy expenditure and decreasing food intake.  The anti-obesity effects 
of IL-6 are not due solely to actions via the central nervous system however (133).  Several 
lines of evidence also support direct peripheral effects of IL-6.  Data presented by Path et al. 
(26) demonstrate autocrine/paracrine actions of IL-6 on adipocytes.  IL-6 and the IL-6 
receptor complex, including the ligand binding α subunit and the signal transducing gp130 
subunit, are expressed in human adipocytes and 3T3-L1 cells (26).  Studies performed in 
vitro further demonstrate that the adipose IL-6 receptor can activate the Jak/STAT pathway 
(134).  Acute exposure of 3T3-L1 adipocytes to recombinant IL-6 results in STAT3 tyrosine 
phosphorylation.  Several groups report the downstream actions of IL-6 in adipose tissue as 
well.  Most importantly, IL-6 stimulates lipolysis, decreases LPL activity and causes a 
notable decline in the uptake of circulating triglycerides, and increases leptin production (26-
30).  The increased lipolysis, decreased LPL activity, and high rates of leptin production in 
response to IL-6 may account for a portion of the weight loss observed in IL-6 treated 
rodents. 
 
2.3  Metabolic Effects of CNTF in WAT 
 
 CNTF was initially recognized for its neuroprotective effects, leading to its evaluation 
in patients suffering from amyotrophic lateral sclerosis (135, 136).  In these clinical trials, 
subcutaneous administration of recombinant CNTF caused unexpected and substantial 
weight loss.  The weight reducing effects of CNTF were further examined and confirmed in 
rodent models of obesity (137-139).  Daily intraperitoneal administration of CNTF to ob/ob 
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mice produces a dose-dependent decrease in body weight characterized by decreased food 
intake and a preferential loss of fat as opposed to lean body mass (137, 138).  Similarly, in 
db/db mice, treatment with CNTF causes dose- and time-dependent weight loss and 
suppression of food intake (137, 139).  Studies performed in DIO mice show similar results 
(137, 138).  CNTF decreases food intake in a dose-dependent manner, resulting in reduced 
body weight and adiposity.   
 
 The adipose reducing effects of CNTF, however, are beyond that that can be 
accounted for by reduced caloric intake alone.  It was suggested therefore, that CNTF, like 
leptin, might have direct effects on adipocytes as well (139).  Recent studies by Zvonic et al. 
(31) confirm this.  CNTF receptor complex proteins, including the α subunit, the LIFR, and 
gp130, are expressed in 3T3-L1 cells.  Studies performed in vitro and in vivo further 
demonstrate that the adipose CNTF receptor can activate the Jak/STAT pathway.  Incubation 
of 3T3-L1 adipocytes with recombinant CNTF results in a dose- and time- dependent 
activation and nuclear translocation of STAT3 (31).  Furthermore, intraperitoneal CNTF 
administration to wild-type mice causes prompt activation of adipocyte STAT3.  Zvonic et 
al. also report the downstream actions of CNTF.  In 3T3-L1 adipocytes, CNTF represses 
FAS gene expression, causes a notable reduction in sterol regulatory element binding 
protein-1 (SREBP-1) protein levels, and a resulting decline in fatty acid biosynthesis.   
Zvonic et al. conclude that the decreased biosynthesis of fatty acids in adipose tissue in 
response to CNTF may account for a portion of the weight loss observed in CNTF treated 
rodents.   
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3.  Midkine  
 Midkine is a secreted heparin-binding growth factor encoded by a retinoic acid 
responsive gene (140).   The mature molecule is a basic, cysteine-rich polypeptide of 
molecular weight 14kDa (141).  Midkine’s biological activities include fibrinolytic, anti-
apoptotic, mitogenic, transforming, and angiogenic ones (142). 
 
3.1  Midkine Signaling 
 Midkine exerts its functions through interaction with specific cell-surface receptors.  
Receptor-type protein tyrosine phosphatase ζ (PTPζ), low-density-lipoprotein-receptor-
related protein (LRP), α4β1- and α6β1-integrins, and anaplastic lymphoma kinase (ALK) have 
been identified as receptors for midkine.  PTPζ is a chondroitin sulfate proteoglycan with an 
intracellular tyrosine phosphatase domain.  Midkine’s interaction with PTPζ is important in 
migration and survival of embryonic neurons (143).  LRP, a member of the LDL-receptor 
family, is involved in the anti-apoptotic activities of midkine (144), while α4β1- and α6β1-
integrins are involved in midkine dependent cell migration and neurite outgrowth (145).  
Finally, ALK, a receptor-type tyrosine kinase, utilizes PI3-kinase and Erk for intracellular 
signaling in the promotion of cell growth (146).  Midkine also utilizes the Jak/STAT pathway 
for midkine dependent cell proliferation (147).   
 
3.2   Biological Effects of Midkine 
 The biological activities of midkine are diverse.  In the nervous system, midkine 
regulates neurite outgrowth and neuron survival (148, 149).  Accumulating evidence is 
defining a role for midkine in oncogenesis as well.  Midkine is overexpressed in a variety of 
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cancers including esophageal (150), gastric (151), colon (152), pancreatic (153),  lung (154), 
and breast (155).  In addition, midkine serves as an autocrine mitogen for tumor cells (147).  
Midkine also possesses transforming properties: forced expression of midkine causes NIH-
3T3 cells to undergo cellular transformation and causes tumor formation in nude mice (156).  
Finally, midkine inhibits the induction of apoptosis (157), promotes angiogenesis (158), and 
stimulates tyrosine phosphorylation of several cellular proteins, including Erk1, Erk2, Akt, 
Jak, and STAT1 (147, 157).   
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CHAPTER III 
MECHANISM OF STAT3 ACTIVATION DURING 3T3-L1 ADIPOGENESIS 
STAT3 is abundantly expressed in preadipocytes and adipocytes, and highly activated 
and bound to DNA in proliferating preadipocytes and adipocytes.  STAT3 activation during 
adipogenesis is delayed, however, suggesting that STAT3 tyrosine phosphorylation occurs by 
an indirect mechanism.  The current work aimed to identify the differentiation-induced 
STAT3 activating factor and determine its role in adipogenesis.  Our findings are presented 
below in the manuscript titled “Midkine is an Autocrine Activator of STAT3 in 3T3-L1 
Cells”. 
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Manuscript #1: Midkine is an Autocrine Activator of STAT3 in 3T3-L1 Cells 
 
Authors:  Erin R. Cernkovich, Jianbei Deng, Kunjie Hua, Joyce B. Harp 
Published in:  Endocrinology.  2007 Apr;148(4):1598-604 
 
A.  ABSTRACT  
 Mitotic clonal expansion is believed to be necessary for 3T3-L1 adipocyte formation.  
Signal transducer and activator of transcription 3 (STAT3), a mitogenic signaling protein, is 
activated through tyrosine phosphorylation during the proliferative phases of adipogenesis.  
We hypothesize that this signaling protein plays a key role in mitotic clonal expansion and 
differentiation.  Here we determined that the adipocyte differentiation cocktail containing 
isobutylmethylxanthine, dexamethasone, and insulin (MDI) induced STAT3 tyrosine 
phosphorylation indirectly through the synthesis of an autocrine/paracrine factor.  We further 
determined that the factor has heparin binding properties, and identified the factor as 
midkine, a pleiotrophic growth factor previously associated with neuronal development and 
oncogenesis.  Recombinant midkine induced STAT3 tyrosine phosphorylation in a time- and 
dose-dependent manner and stimulated the proliferation of post-confluent 3T3-L1 cells.  
Midkine neutralizing antibodies inhibited differentiation-induced STAT3 tyrosine 
phosphorylation as well as adipogenesis.  These results show that MDI-induced synthesis and 
release of midkine explains the delayed activation of STAT3 during adipogenesis, and that 
the midkine-STAT3 signaling pathway plays a necessary role in mitotic clonal expansion and 
differentiation. 
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B.  INTRODUCTION 
 Obesity occurs when energy intake chronically exceeds energy expenditure.  Excess 
energy is stored in adipose tissue as triacylglycerol (159).  To accommodate the increased 
triacylglycerol, adipose tissue expands, primarily through an increase in fat cell size.  Upon 
reaching a critical size, enlarged adipocytes secrete factors that promote preadipocytes to 
proliferate and differentiate into adipocytes (160).  Although much is known about the 
mechanisms of preadipocyte differentiation, less is known about the mechanisms of 
preadipocyte proliferation.  
 
 Many of the advances in our understanding of adipogenesis are based on studies in 
3T3-L1 cells.  3T3-L1 preadipocytes are fibroblast-like cells committed to the adipocyte 
lineage.   In culture, 3T3-L1 preadipocytes replicate until they form a confluent monolayer 
(6).  At confluence, cell-cell contact triggers growth arrest.  When induced with hormonal 
agents, often a cocktail of isobutylmethylxanthine, dexamethasone, and insulin (MDI), 
growth-arrested preadipocytes reenter the cell cycle and undergo 1-2 rounds of cell division 
known as mitotic clonal expansion (7).  Following mitotic clonal expansion, preadipocytes 
exit the cell cycle, commit to terminal differentiation, and begin to express adipocyte specific 
genes (8).   
 
 The major transcriptional regulators of adipogenesis include proteins belonging to the 
CCAAT/enhancer binding protein (C/EBP) family and the peroxisome proliferator-activated 
receptor (PPAR) superfamily.  Signal transducers and activators of transcription (STATs) 
have also been implicated in the differentiation program.  A coordinated cascade involving 
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the above mentioned factors typifies the differentiated phenotype (9-11).  Specifically, 
mitotic clonal expansion is characterized by a transient increase in the expression of the 
transcription factors C/EBPβ (38) and δ (38), as well as the tyrosine phosphorylation and 
activation of STAT3 (16).  Furthermore, acquisition of the terminally differentiated 
phenotype depends on transcriptional activation of C/EBPα and PPARγ (161). 
 
 Midkine is a secreted heparin-binding growth factor encoded by a retinoic acid 
responsive gene (140).   The mature molecule is a basic, cysteine-rich polypeptide of 
molecular mass 14kDa (141).  Midkine’s biological activities are diverse, and include 
regulation of neurite outgrowth and neuron survival (148, 149).  Accumulating evidence is 
defining a role for midkine in oncogenesis as well.  Midkine is overexpressed in a variety of 
cancers including esophageal (150), gastric (151), colon (152), pancreatic (153),  lung (154), 
and breast (155).  Additionally, midkine serves as an autocrine mitogen for tumor cells.  
Midkine also possesses transforming properties: forced expression of midkine causes NIH-
3T3 cells to undergo cellular transformation and causes tumor formation in nude mice (156).  
Finally, midkine inhibits the induction of apoptosis (157), promotes angiogenesis (158), and 
stimulates tyrosine phosphorylation of several cellular proteins, including STAT1 (147, 157). 
 
 In this report, we identified a midkine-STAT3 signaling pathway that plays a 
necessary role in mitotic clonal expansion and differentiation. 
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C.  MATERIALS AND METHODS 
 
Materials 
 3T3-L1 cells were purchased from ATCC (Manassas, VA).  Affinity-purified rabbit 
polyclonal phosphotyrosine 705-specific anti-STAT3 (STAT3-PY) and rabbit polyclonal 
anti-STAT3 were purchased from Cell Signaling (Beverly, MA).  Affinity-purified rabbit 
polyclonal anti-C/EBPα, mouse monoclonal anti-PPARγ, human polyclonal anti-midkine and 
normal goat IgG were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  
Recombinant human midkine was purchased from R&D Systems (Minneapolis, MN).  The 
enhanced chemiluminescence detection kit and horseradish peroxidase-conjugated secondary 
antibodies were purchased from Pierce Biotechnology, Inc. (Rockford, IL). The HiTrapTM 
Heparin HP column was purchased from Amersham Pharmacia (Piscataway, NJ ). 
 
Cell culture 
 3T3-L1 preadipocytes were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% v/v fetal bovine serum (FBS), 10 mg/ml streptomycin, 100 U/ml 
penicillin, and 1 mM pyruvate at 37°C in 5% CO2 air.  3T3-L1 cells were studied as pre- and 
post-confluent preadipocytes and as adipocytes.  To induce differentiation, 2-day post-
confluent cells were treated with 0.5µM dexamethasone, 0.5 mM isobutylmethylxanthine, 
and 10µg/ml insulin in DMEM/10% FBS for 72 hours.  On day 3, the differentiation medium 
was replaced with DMEM/10% FBS, which was changed every 2 days thereafter until 
analysis. 
 
Immunoblot analysis  
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 3T3-L1 cells were washed twice in PBS with 1 mM orthovanadate, then placed 
 immediately in sample buffer (1% Nonidet P-40, 20 mM Tris-HCL (pH 8.0), 150 mM NaCl, 
1 mM EDTA, 0.1% NaN3, 10 µg/ml aprotinin, 1 µM pepstatin, 16.4 µg/ml leupeptin, 1 mM 
phenylmethyl-sulfonylfluoride, 0.1 mM Na3VO4, 2% SDS, 10% glycerol) without 
dithiothreitol or tracking dye.  Lysates were heated and protein concentrations were 
determined using Bio-Rad Laboratories, Inc., DC Protein Assay kit (Richmond, CA).  
Bovine serum albumin (BSA) was used as a standard.  Samples were heated for 2 minutes at 
85°C, separated by 10% SDS-PAGE, and analyzed by immunoblotting as previously 
described (16).  Immunoblots were developed using the enhanced chemiluminescence kit.  
 
RNA isolation   
 Total RNA was isolated from 3T3-L1 cells using the RNeasy mini kit (Qiagen, Inc., 
Valencia, CA) at 0, 1, 3, 6, 24, 48, and 72 hours after induction of differentiation.  RNA 
quality was confirmed by ethidium bromide staining and detection of intact 28S and 18S 
ribosomal RNA bands. 
 
Reverse transcriptase PCR   
 Deoxyribonuclease-treated RNA, collected 0, 1, 3, 6, 24, 48, and 72 hours after 
induction of differentiation, was reversed transcribed using the Qiagen OneStep RT-PCR kit 
(Qiagen, Inc., Valencia, CA).  5’ACCGAGGCTTCTTCCTTCTCGCCCTTCTTGCCC3’ and 
5’CCCTGCACCTCCAAGACCAAGTCAAAGACC3’ were used as forward and reverse 
primers respectively. 
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Heparin affinity column 
 Twenty-four hour conditioned medium (CM) was applied to a Hi TrapTM Heparin HP 
column.  The column was washed with 0.02 M Tris-HCl (pH 7.5), and eluted with NaCl in 
doses ranging from 0 M to 2 M.  To concentrate and desalt the eluted fractions, fractions 
were centrifuged three times at 5500 rpm for 45 minutes at 4ºC.   
 
Midkine neutralization assay 
 Recombinant human midkine at a concentration of 10.0ng/ml was neutralized with 
anti-midkine antibody (M-18), in doses ranging from 0.1 µg/ml to 10.0 µg/ml, for 1 hour at 
37ºC.  Post-confluent preadipocytes were stimulated with recombinant human midkine, or 
recombinant human midkine neutralized with anti-midkine antibody.  Cells were harvested 
after 10 minutes of treatment. 
 
 CM collected 24 hours after stimulation with MDI (A1 CM) was neutralized with 
10.0 µg/ml normal goat IgG or 10.0 µg/ml anti-midkine antibody (M-18) for 1 hour at 37ºC.  
Post-confluent preadipocytes were stimulated with A1 CM, or A1 CM neutralized with 10.0 
µg/ml normal goat IgG or 10.0 µg/ml anti-midkine antibody.  Cells were harvested after 10 
minutes of treatment. 
 
Proliferation assay 
 Preconfluent 3T3-L1 preadipocytes were seeded in 96-well plates at a density of 2000 
cells/100µl/well.  Cells were seeded in DMEM containing 10% FBS. Vehicle (PBS), 10.0 
ng/ml recombinant human midkine, or MDI was added to culture medium with or without 
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cells at 2-days post-confluence.  At 0, 24, 48, and 72 hours after stimulation, a colorimetric 
proliferation assay (CellTiter 96 Aqueous nonradioactive cell proliferation assay; Promega, 
Madison, WI) was performed as directed by the manufacturer.  To calculate the absorbance 
values at each time point, the mean absorbance of two blank wells (containing vehicle, 
recombinant human midkine, or MDI in culture medium without cells) was subtracted from 
the mean absorbance of three wells containing cells. 
 
Oil Red O staining 
 Eight-twelve days after induction of differentiation, 3T3-L1 adipocytes were washed 
with PBS, fixed with 3.7% formaldehyde in PBS, then stained with 0.5% Oil Red-O. 
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D.  RESULTS  
An autocrine/paracrine factor induces STAT3 activation in 3T3-L1 cells.   
STAT3 is activated within the first 24 hours after induction of differentiation (10).  
To better define the timing of MDI-induced STAT3 tyrosine phosphorylation, cell lysates 
were recovered 1, 3, 6, 12 and 24 h after MDI stimulation.  STAT3 tyrosine phosphorylation 
was not observed until 3 hours after the induction of differentiation (Figure 3.1).  This 3 hour 
delay in STAT3 activation is not consistent with the immediate tyrosine phosphorylation that 
typically occurs minutes after ligand stimulation (162).  This data suggests that induction of 
differentiation with MDI stimulates the tyrosine phosphorylation of STAT3 by an indirect 
mechanism.  
 
To determine whether MDI induces the release of a STAT3 activating factor, post-
confluent preadipocytes were induced to differentiate with MDI, and CM was collected 5 
minutes and 24 hours following stimulation.  Unstimulated post-confluent preadipocytes 
were then stimulated with either the 5 minute CM or the 24 hour CM for 5 minutes.  
Treatment of unstimulated preadipocytes with 24 hour CM induced STAT3 tyrosine 
phosphorylation, suggesting that MDI stimulated the release of a STAT3 activating factor 
over the 24 hour period (Figure 3.2A).  Treatment of unstimulated preadipocytes with 5 
minute CM however, did not induce STAT3 activation, suggesting that release of the 
activating factor had not occurred within this short time frame.   
 
To determine the cellular source of the STAT3 activating factor, we next collected 
CM daily from 3T3-L1 cells at various stages of proliferation and differentiation.       
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Figure 3.1 – Pattern of STAT3 activation in 3T3-L1 preadipocytes. 
Whole cell lysates were prepared from 3T3-L1 cells at various times (0, 1, 3, 6, 12, and 24 
hours) after induction of differentiation with MDI.  Western blot analysis (IB) was performed 
with anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-STAT3 
antibody.  Results are representative of 3 separate experiments. 
 
 
 
 
 
 
   
Figure 3.2 – Effect of CM stimulation on STAT3 tyrosine phosphorylation in 3T3-L1 
preadipocytes and adipocytes.   
(A)  3T3-L1 preadipocytes were cultured in the presence of CM generated 5 minutes after 
stimulation with MDI, or CM generated 24 hours after stimulation with MDI.  After a 5 
minute stimulation, whole cell lysates were prepared and Western blot analysis (IB) was 
performed with anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-
STAT3 antibody.   
(B)  3T3-L1 preadipocytes were cultured in the presence of CM generated 1, 2, 3, 5, 7, or 8 
days after stimulation with MDI.  After a 5 minute stimulation, whole cell lysates were 
prepared and Western blot analysis was performed with anti-STAT3-PY antibody.  Blots 
were stripped and re-probed with anti-STAT3 antibody.  Results are representative of 3 
separate experiments. 
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Unstimulated post-confluent preadipocytes were then stimulated with this CM.  As shown in 
Figure 3.2B, CM from post-confluent proliferating preadipocytes (1 and 2 days after 
induction of differentiation) induced STAT3 tyrosine phosphorylation.  STAT3 tyrosine 
phosphorylation was barely detectable, however, in cells stimulated with CM from growth-
arrested preadipocytes (0) and adipocytes (3-8).  
 
Transcription and translation are required for autocrine/paracrine activation of 
STAT3. 
 As 24 hour CM induced STAT3 tyrosine phosphorylation, but 5 minute CM did not, 
we hypothesized that the STAT3 activating factor was synthesized de novo in response to 
MDI.  Post-confluent preadipocytes were pretreated with cycloheximide or actinomycin D 
prior to generation of 24 hour CM.  A new group of post-confluent preadipocytes was then 
stimulated with the inhibitor pretreated CM for 5 minutes.  Inhibition of protein synthesis 
with cycloheximide during the generation of CM significantly reduced CM-induced STAT3 
tyrosine phosphorylation (Figure 3.3A).  Blockade of mRNA synthesis with actinomycin D 
completely inhibited CM-induced STAT3 tyrosine phosphorylation, indicating that RNA 
synthesis is required to generate the STAT3 activating factor.    
 
Identification of a heparin binding autocrine/paracrine factor. 
 Efforts to identify the activating factor were first directed towards the traditional 
activator of STAT3, IL-6.  We determined in a series of studies that IL-6 was released from 
post-confluent preadipocytes and that IL-6 activated STAT3 in these cells.  However, 
removal of IL-6 from the CM had no effect on STAT3 tyrosine phosphorylation (data not  
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Figure 3.3 – Effects of cycloheximide, actinomycin D, and heparin affinity column 
pretreatment on CM-induced activation of STAT3. 
 (A)  3T3-L1 preadipocytes were cultured in the presence of 24 hour CM generated by 
preadipocytes pretreated with either 10.0µg/ml cycloheximide or 5.0µg/ml actinomycin D.   
After a 5 minute stimulation, whole cell lysates were prepared and Western blot analysis (IB) 
was performed with anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-
STAT3 antibody.   
(B)  3T3-L1 preadipocytes were cultured in the presence of 24 hour CM eluted from a 
heparin affinity with increasing concentrations of NaCl (0.5M, 1.0M, 1.5M, or 2.0M).   After 
a 5 minute stimulation, whole cell lysates were prepared and Western blot analysis was 
performed with anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-
STAT3 antibody.  Results are representative of 3 separate experiments. 
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shown).  This indicated that IL-6 was not responsible for the autocrine/paracrine activation of 
STAT3. 
 
 Because STAT3 has been implicated in the proliferative phases of adipogenesis, 
efforts to identify the activating factor were next directed towards factors known to stimulate 
preadipocyte proliferation.  Heparin binding growth factors are released into the culture 
medium and act as autocrine/paracrine factors contributing to preadipocyte proliferation 
(160).  Therefore, to narrow our search, we determined whether the STAT3 activating factor 
had heparin binding properties.  Twenty-four hour CM was applied to a heparin affinity 
column and eluted with increasing concentrations of NaCl.  Treatment of unstimulated post-
confluent preadipocytes with 24 hour CM eluted from the heparin affinity column induced 
STAT3 tyrosine phosphorylation (Figure 3.3B).  The greatest effect was seen with CM 
eluted at 1-2 M NaCl.  This led us to search for STAT3 activating ligands with heparin 
binding properties. 
 
Midkine is the autocrine/paracrine activator of STAT3. 
The heparin-binding growth factor midkine is a regulator of normal and transformed 
cell proliferation.  Additionally, midkine stimulates tyrosine phosphorylation of STAT1 in 
other cell lines (147).  Therefore, we tested the ability of recombinant midkine to activate 
STAT3 in 3T3-L1 cells.  Post-confluent preadipocytes were cultured in the presence of 
varying doses of recombinant midkine and STAT3 tyrosine phosphorylation was measured 
by western blot analysis at several time points following stimulation.  As shown in Figure 
3.4A, the addition of midkine induced STAT3 tyrosine phosphorylation in a dose-dependent  
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Figure 3.4 – Effect of recombinant midkine stimulation on STAT3 tyrosine 
phosphorylation in 3T3-L1 preadipocytes.   
(A)  3T3-L1 preadipocytes were cultured in the presence of varying concentrations 
(0.1ng/ml, 1.0ng/ml, 10.0ng/ml, or 100.0ng/ml) of recombinant midkine (rhMK).  After a 10 
minute stimulation, whole cell lysates were prepared and Western blot analysis (IB) was 
performed with anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-
STAT3 antibody.       
(B)  3T3-L1 preadipocytes were cultured in the presence of 10.0ng/ml rhMK.  After a 1, 5, 
10, 30, or 60 minute stimulation, whole cell lysates were prepared and Western blot analysis 
was performed with anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-
STAT3 antibody.  Results are representative of 3 separate experiments.  
 
 
 
 
 
 
Figure 3.5 – Midkine expression in 3T3-L1 preadipocytes.   
Midkine expression in 3T3-L1 cells 0, 1, 3, 6, 24, 48, and 72 hours following induction of 
differentiation with MDI was measured by RT-PCR. 
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manner.  Figure 3.4B shows that midkine also induced STAT3 tyrosine phosphorylation in a 
time-dependent manner.  Because STAT3 tyrosine phosphorylation peaked following a 10 
minute stimulation with 10.0 ng/ml recombinant midkine, this time and dose were used for 
all subsequent experiments.  
 
Earlier studies confirmed that the STAT3 activating factor was synthesized following 
stimulation with MDI (Figure 3.3A).  To determine whether midkine is expressed in 3T3-L1 
cells, we measured midkine expression at several time points following stimulation with 
MDI using RT-PCR.  Oligonucleotide primers were used to amplify a 386 bp fragment of 
mouse midkine.  Figure 3.5 shows that midkine is expressed in 3T3-L1 preadipocytes, and 
that midkine expression coincides with MDI-induced STAT3 tyrosine phosphorylation.  The 
386bp fragment was sequenced and confirmed to be midkine (data not shown).       
 
As midkine is a heparin binding growth factor expressed in 3T3-L1 cells, and because 
recombinant midkine activates STAT3 in 3T3-L1 cells, we hypothesized that midkine was 
the autocrine/paracrine activator of STAT3.  Consequently, we hypothesized that neutralizing 
midkine in CM would lead to a decrease in CM-induced STAT3 tyrosine phosphorylation.  
First, to confirm efficient neutralization, recombinant midkine was neutralized with varying 
concentrations of anti-midkine antibody.  Figure 3.6A shows that midkine was efficiently 
neutralized with 10.0 µg/ml anti-midkine antibody.  Although there were decreases in 
STAT3 tyrosine phosphorylation, STAT3 protein levels did not change.   
 
Next, to demonstrate specificity of the neutralizing antibody, recombinant IL-6 was 
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Figure 3.6 – Effect of midkine neutralization on midkine-induced STAT3 tyrosine 
phosphorylation in 3T3-L1 preadipocytes.  
(A)  3T3-L1 preadipocytes were cultured in the presence of 10.0ng/ml recombinant midkine 
(rhMK) neutralized with varying concentrations of anti-midkine antibody (0.1µg/ml, 
1.0µg/ml, or 10.0µg/ml).  After a 5 minute stimulation, whole cell lysates were prepared and 
Western blot analysis (IB) was performed with anti-STAT3-PY antibody.  Blots were 
stripped and re-probed with anti-STAT3 antibody.   
(B)  3T3-L1 preadipocytes were cultured in the presence of 10.0ng/ml recombinant IL-6 
neutralized with 10.0µg/ml anti-midkine antibody.  After a 5 minute stimulation, whole cell 
lysates were prepared and Western blot analysis was performed with anti-STAT3-PY 
antibody.  Blots were stripped and re-probed with anti-STAT3 antibody.       
(C)  3T3-L1 preadipocytes were cultured in the presence of 24 hour CM neutralized with 
10.0µg/ml anti-midkine antibody or 10.0µg/ml normal goat IgG.   After a 5 minute 
stimulation, whole cell lysates were prepared and Western blot analysis was performed with 
anti-STAT3-PY antibody.  Blots were stripped and re-probed with anti-STAT3 antibody.  
Results are representative of 3 separate experiments.            
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neutralized with 10.0 µg/ml anti-midkine antibody.  Figure 3.6B shows that anti-midkine 
antibody did not block IL-6-induced STAT3 tyrosine phosphorylation.  Upon confirming the 
efficiency and specificity of the neutralizing antibody, 24 hour CM was neutralized with 10.0 
µg/ml anti-midkine antibody.  Post-confluent preadipocytes were then stimulated with the 
neutralized CM.  Figure 3.6C shows that 24 hour CM-induced STAT3 tyrosine 
phosphorylation was significantly reduced following the addition of anti-midkine antibody.  
Addition of control IgG, however, did not effect 24 hour CM-induced STAT3 activation.  
These data suggest that midkine is primarily responsible for the autocrine/paracrine 
activation of STAT3. 
 
Midkine is sufficient for mitotic clonal expansion. 
We previously reported that activated STAT3 plays a regulatory role during the 
proliferative phases of adipogenesis (16).  Because midkine is the autocrine/paracrine 
activator of STAT3, we hypothesized that recombinant midkine would be sufficient to 
stimulate 3T3-L1 proliferation.  To elucidate a role for midkine in mitotic clonal expansion, 
post-confluent preadipocytes were cultured in the presence of 10.0 ng/ml recombinant 
midkine, and cell proliferation was measured at several points following stimulation.  
Although not as potent as MDI, the addition of recombinant midkine to post-confluent 
preadipocytes promoted their proliferation or at a minimum maintained cell number in a 
time-dependent manner relative to cells in medium containing 10% FBS (Figure 3.7).  These 
results are consistent with other studies suggesting that heparin binding growth factors 
contribute to the development of adipocyte hyperplasia (160). 
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Figure 3.7 – Effect of recombinant midkine stimulation on the proliferation phases of 
adipogenesis.   
Post-confluent preadipocytes were cultured in the presence of vehicle (PBS), 10.0ng/ml 
recombinant midkine (rhMK), or MDI.  The degree of preadipocyte proliferation was 
determined via a colorimetric proliferation assay 0, 24, 48, and 72 hours following 
stimulation.  Data shown reflect the means ± SE of 9 experiments.  *, P < 0.05 when the 
vehicle group was compared to the midkine group for each time point by t test.   
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Midkine is necessary for adipogenesis. 
Mitotic clonal expansion is required for progression through the differentiation 
program (37, 39, 40).  Mitotic clonal expansion and stimulators of this process, however, 
may or may not be sufficient to induce differentiation in the absence of MDI.  To determine 
the effect of exogenous midkine on differentiation, post-confluent preadipocytes were 
cultured in the presence of 10.0 ng/ml recombinant midkine for 72 hours.  From days 3-8, 
cells were maintained in culture medium alone.  At various times after stimulation with 
recombinant midkine, expression of adipogenic transcription factors and accumulation of 
cytoplasmic triglyceride were assessed.  Cells treated with recombinant midkine neither 
accumulated cytoplasmic triglyceride nor expressed adipogenic transcription factors (data not 
shown), suggesting that midkine is not sufficient for adipogenesis.   
 
To determine if midkine is necessary for adipogenesis, post-confluent preadipocytes 
were stimulated with MDI or MDI neutralized with 1.0 µg/ml anti-midkine antibody for 48 
hours.  From days 2-8, cells were maintained in culture medium alone.  At various times after 
stimulation with MDI or MDI plus anti-midkine antibody, expression of adipogenic 
transcription factors and accumulation of cytoplasmic triglyceride were assessed.  Cells 
treated with MDI plus anti-midkine antibody accumulated significantly less triglyceride than 
cells treated with MDI alone as shown by Oil Red-O staining (Figure 3.8B).  Consistent with 
these results, expression of the adipogenic transcription factors C/EBPα and PPARγ was also 
significantly reduced (Figure 3.8A).  Stimulation with MDI plus control IgG did not affect 
C/EBPα or PPARγ expression.  These data suggest that midkine is necessary for 
adipogenesis. 
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Figure 3.8 – Effect of midkine neutralization on adipogenesis. 
3T3-L1 preadipocytes were cultured in the presence of MDI containing 1.0µg/ml anti-
midkine antibody or 1.0µg/ml normal goat IgG for 2 days.  (A)  Whole cell lysates were 
prepared on day 4 and day 6, and expression of adipogenic transcription factors (C/EBPα and 
PPARγ) was assessed by Western blot analysis (IB).  Blots were stripped and re-probed with 
anti-STAT3 antibody.  (B)  On day 8, cells were stained with Oil-Red O.  
 
 
 
 
 
 
 
 
IB:  C/EBPα 
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E. DISCUSSION 
 The present study reports the identification of a midkine-STAT3 signaling pathway 
that plays a necessary role in adipogenesis.  This investigation was prompted by our initial 
observation that STAT3 activation during adipogenesis was delayed.  These results suggested 
that a mechanism other than direct activation by MDI was involved.  Our data showing 
immediate STAT3 tyrosine phosphorylation following stimulation with CM confirmed the 
involvement of an autocrine/paracrine factor.  The fact that the autocrine/paracrine factor was 
identified only in CM from differentiating preadipocytes and not in CM from growth-arrested 
preadipocytes and adipocytes suggested that the factor was synthesized and released in a 
differentiation-dependent manner, and thus likely important in the regulation of adipogenesis.  
Our data showing inhibitory effects of cycloheximide and actinomycin D on this factor 
provided strong evidence for endogenous production of the factor, rather than conversion or 
generation of the factor from one of the components of the differentiation cocktail.  
Furthermore, our findings that midkine mRNA expression preceded the appearance of the 
STAT3 activating factor in CM, and midkine antibodies neutralized the STAT3 activating 
effects of CM, confirmed the identify of the autocrine activator as midkine.  Because a 
sensitive method to detect rodent midkine protein was not available, we were not able to 
measure midkine levels in CM.   
 
Leukemia inhibitory factor, oncostatin M, and IL-6, potent activators of STAT3 in 
3T3-L1 cells, are capable of activating STAT3 at nanomolar or ng/ml doses (134).  In the 
present study we report that midkine also activates STAT3 in 3T3-L1 cells at ng/ml 
concentrations.  In the context of the above mentioned traditional activators, these data 
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demonstrate that midkine is a relatively potent activator of STAT3.  Also in this dose range, 
midkine was sufficient to simulate post-confluent preadipocyte proliferation.  Although the 
effect of midkine on proliferation was small when compared to the effect of MDI, midkine 
clearly enhanced cell number when compared to the effect of serum containing medium 
alone.  Because it is well established that the individual components of MDI do little to 
induce differentiation when used alone, the small effect of midkine on clonal expansion was 
not surprising (16, 34).  By contrast, the inhibitory effect of midkine neutralization on 
differentiation was near complete.  This led us to the important conclusion that midkine is 
necessary but not sufficient to induce mitotic clonal expansion and subsequent 
differentiation.  
 
These findings are consistent with other studies demonstrating that midkine is a 
regulator of normal and transformed cell proliferation.  Under physiological conditions, 
midkine stimulates the proliferation of fibroblasts (163) and skeletal muscle myoblasts (164).  
The finding that midkine is overexpressed in a number of cancer cell lines and primary 
tumors (150-155, 165) implicates it in abnormal proliferation and carcinogenesis as well.  
Midkine has also been shown to serve as an autocrine mitogen for tumor cells (147), possess 
transforming properties (156), inhibit apoptosis (157), and promote angiogenesis (158).  
 
Lastly, the midkine-related findings described in this report may have clinical 
relevance.  It was previously reported that preadipocytes from massively obese persons 
replicate to a significantly higher degree than preadipocytes from lean persons (166), and that 
their exaggerated proliferative capacity is due in part, to the augmented production of 
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mitogenic proteins.  These mitogenic factors are released into the culture medium and act as 
autocrine/paracrine factors contributing to adipocyte hyperplasia (166).  Because heparin 
binding growth factors are the mitogenic factors released by preadipocytes from both lean 
and massively obese persons (160), it is quite possible based on the findings in this report, 
that midkine plays a role in the increased cellularity associated with some forms of obesity. 
 
In summary, we provided evidence in this report that midkine is an autocrine 
activator of STAT3 during early phases of adipogenesis.  We also demonstrated that midkine 
itself induces preadipocyte proliferation likely through a STAT3 signaling pathway and 
concluded that the midkine/STAT3 pathway is necessary for adipogenesis.  These data 
provide insight into the complexity of the early stages of adipocyte differentiation and 
highlight the importance of tyrosine phosphorylation in the proliferative phases of 
adipogenesis.  Further studies are needed to determine midkine’s mechanism of STAT3 
activation (i.e., receptor and associated non-receptor tyrosine kinase) as the midkine/STAT3 
pathway may play a role in the development of adipocyte hyperplasia and severe obesity.
 
57 
CHAPTER IV  
ROLE OF STAT3 IN ADIPOGENESIS AND ADIPOCYTE METABOLISM IN MICE 
 Manuscript #1 (Chapter III) identified a midkine-STAT3 signaling pathway that is 
necessary for adipogenesis.  To build on this research finding, the current work aimed to 
determine the physiological role of STAT3 in adipogenesis in animals.  Mice with an 
adipocyte-specific disruption of the STAT3 gene (ASKO mice), created using aP2-Cre-loxP 
DNA  recombination, and primary preadipocyte isolated from ASKO mice, were studied to 
achieve this aim.  Our findings are presented below in the manuscript titled “Adipocyte-
Specific Disruption of Signal Transducer and Activator of  Transcription 3 (STAT3) 
Increases Body Weight and Adiposity”. 
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Manuscript #2: Adipocyte-Specific Disruption of Signal Transducer and Activator  
                                    of Transcription 3 (STAT3) Increases Body Weight And Adiposity 
 
Authors:  Erin R. Cernkovich, Jianbei Deng, Michael C. Bond, Terry P. Combs, 
   Joyce B. Harp 
 
Under review:  Cell Metabolism 
 
 
A.  ABSTRACT   
  To determine the role of STAT3 in adipose tissue, we used Cre-loxP DNA 
recombination to create mice with an adipocyte-specific disruption of the STAT3 gene 
(ASKO mice).  aP2-Cre driven disappearance of STAT3 expression occurred on day 6 of 
adipogenesis, a time point when preadipocytes have already undergone conversion to 
adipocytes.  Thus, this knockout model examined the role of STAT3 in mature, but not 
differentiating adipocytes.  Beginning at 9 weeks of age, ASKO mice weighed more than 
their littermate controls and had increased adipose tissue mass, associated with adipocyte 
hypertrophy, but not adipocyte hyperplasia, hyperphagia, or reduced energy expenditure.  
Leptin-induced, but not isoproterenol-induced, lipolysis was impaired in ASKO adipocytes, 
which may partially explain the increased cell size.  Despite reduced adiponectin and 
increased liver triacylglycerol, ASKO mice displayed normal glucose tolerance.  Overall, 
these findings demonstrate that adipocyte STAT3 regulates body weight homeostasis in part 
through direct effects of leptin on adipocytes. 
 
 
   
59 
B.  INTRODUCTION  
 Obesity is a significant medical and public health concern due to its prevalence, 
associated co-morbidities and economic impact (1).  At the cellular level obesity is 
characterized by an increase in adipose tissue mass; which occurs when adipocytes increase 
in size, through the storage of excess energy as triacylglycerol, and/or when adipocytes 
increase in number, through the conversion of preadipocyte to adipocytes (167).   
 
The process of fat cell formation or adipogenesis is triggered by extracellular factors 
that mediate a series of coordinated intracellular events culminating in the expression and 
activation of several transcription factors.  Members of the C/EBP and PPAR families are 
well known to regulate these processes (168).  Recent studies have implicated members of 
the STAT family of transcription factors in adipogenesis as well (15, 16).  STAT3, for 
example, is abundantly expressed in preadipocytes and adipocytes (15), and highly activated 
and bound to DNA in proliferating preadipocytes and adipocytes (16).  In addition, inhibition 
of endogenous STAT3 expression with antisense morpholino oligonucleotides significantly 
decreases preadipocyte proliferation (16).  Although, changes in expression and activation of 
STAT3 occur throughout adipogenesis, the precise role of this transcription factor in 
preadipocyte proliferation and conversion to adipocytes is not yet known.  
 
 The weight-reducing effects of the STAT3 activating ligands leptin, interleukin-6 (IL-
6), and ciliary neurotrophic factor (CNTF) also implicate STAT3 in the regulation of 
adipocyte size.  These cytokines have been shown to regulate fat cell size via direct 
peripheral effects on adipocytes.   Leptin regulates fat cell size peripherally by stimulating 
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white adipose tissue (WAT) lipolysis, inhibiting lipogenesis, and promoting fatty acid 
oxidation (18-25) .  IL-6 also stimulates WAT lipolysis and has been shown to cause a 
notable decline in the uptake of circulating TAG by decreasing lipoprotein lipase activity 
(26-30).  Similarly, CNTF inhibits WAT fatty acid biosynthesis via repression of fatty acid 
synthase (FAS) and sterol regulatory element binding protein-1 (SREBP-1) gene expression 
(31, 32).  It is thought that the anti-lipogenic and pro-lipolytic actions of leptin, IL-6 and 
CNTF, may account for a portion of the weight reducing effects of these cytokines.  Because 
STAT3 is a downstream target of leptin, IL-6 and CNTF signaling, STAT3 likely mediates 
many of the effects of these cytokines in adipocytes.  The contribution of STAT3 to these 
aspects of body weight homeostasis, however, has yet to be determined. 
 
 To determine the role of STAT3 in adipogenesis and body weight homeostasis, we 
generated mice with an adipocyte-specific disruption of the STAT3 gene using aP2-Cre-loxP 
DNA recombination.  The late deletion of STAT3 induced by the aP2 promoter, and the 
resulting preservation of STAT3 expression in preadipocytes prevented us from examining 
the role of STAT3 in adipogenesis.  Therefore, this report examines the role of STAT3 in 
mature adipocytes.  Here, we reveal that adipocyte STAT3 is essential for body weight 
homeostasis and its deficiency causes higher body weight and increased adiposity.  
Furthermore, ASKO mice have reduced serum adiponectin levels and increased liver lipid 
deposits but do not develop impaired glucose tolerance or other obesity-related metabolic 
perturbations.  Thus, ASKO mice represent a model of obesity dissociated from impaired 
glucose tolerance and their characterization provides insight into the physiological roles of 
STAT3 in adipocyte metabolism. 
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C.  MATERIALS AND METHODS 
Construction of the STAT3 targeting vector 
  A STAT3 targeting vector was constructed that introduced loxP sites upstream and 
downstream of exon 22.  The OSfrt-loxP plasmid (kindly provided by the Animal Models 
Core at the University of North Carolina at Chapel Hill) served as the backbone for the 
STAT3 targeting vector.  STAT3 homologous sequences were amplified and cloned into the 
OSfrt-loxP plasmid containing the neomycin resistance (neo) gene, the herpes simplex virus 
thymidine kinase gene, FRT sites flanking neo to facilitate removal of neo by FlpE 
recombinase, a loxP site to facilitate removal of the targeted exon by Cre recombinase, and 
five unique restriction sites.  The long arm of homology, spanning exon 21 of the STAT3 
gene, was amplified from 129/SvEv genomic DNA.  PCR amplification introduced a SpeI 
restriction site and an AgeI restriction site at the 5’ end and 3’ end respectively.  The 
resulting 3.3 kb PCR product was SpeI/AgeI digested and cloned into a SpeI/AgeI digested 
OSfrt-loxP plasmid.  The short arm of homology, spanning exon 23 and 24 of the STAT3 
gene, was amplified from 129/SvEv genomic DNA.  PCR amplification introduced a BamHI 
restriction site and a SalI restriction site at the 5’ end and 3’ end respectively.  The resulting 
2.4 kb PCR product was BamHI/SalI digested and cloned into a BamHI/SalI digested OSfrt-
loxP plasmid containing the long arm.  The target arm, spanning exon 22 of the STAT3 gene 
and including a tyrosine residue necessary for STAT3 activation, was amplified from 
129/SvEv genomic DNA.  PCR amplification introduced a loxP site upstream of exon 22, 
and an AgeI restriction site and a XhoI restriction at the 5’ end and 3’ end respectively.  The 
resulting 339 bp PCR product was AgeI/XhoI digested and cloned into an AgeI/XhoI 
digested OSfrt-loxP plasmid containing the long arm and short arm.       
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Generation of STAT3flox/+ mice 
  2 x 107 129/SvEv embryonic stem cells were transfected with 20.0µg of the linearized 
STAT3 targeting vector by electroporation (250µF/300V).  Cells were subjected to selection 
with G418 and gancyclovir.  Surviving colonies were picked after 12-14 days of selection 
and screened for homologous recombination by PCR and Southern blot analysis.  ES cell 
clones carrying the desired homologous recombination event were expanded.  To remove 
neo, expanded clones were electroporated with a vector that transiently expresses FlpE 
recombinase (kindly provided by the Animal Models Core at the University of North 
Carolina at Chapel Hill).  Deletion of the selection cassette was confirmed by PCR and 
Southern blot analysis.  Targeted clones not containing neo were microinjected into 
blastocysts derived from C57BL/6 females.  To generate mice chimeric from the targeted ES 
cells and host blastocysts (STAT3flox/+), microinjected blastocysts were transferred to the 
uterus of pseudopregnant C57BL/6 recipients.  Chimeric mice (as determined by coat color) 
were then bred with C57BL/6 mice to transmit the targeted allele through the mouse 
germline.  The presence of the targeted allele in the agouti-colored offspring was confirmed 
by PCR. 
 
Generation of adipose tissue-specific STAT3 knockout mice 
 Agouti mice heterozygous for the targeted STAT3 gene (STAT3flox/+) were crossed 
with transgenic mice expressing Cre recombinase under the control of the adipocyte specific 
aP2 promoter/enhancer (B6.Cg-Tg (Fabp4-cre) 1Rev/J, Jackson Laboratories, Bar Harbor 
Maine).  Offspring inheriting both the targeted allele and the Cre-expressing transgene (aP2-
Cre STAT3flox/+) were intercrossed to yield six derivative strains:  (a) STAT3+/+ (WT), (b) 
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STAT3flox/+ (WT), (c) STAT3flox/flox (WT), (d) STAT3+/+/Cre (WT), (e) STAT3flox/+/Cre 
(HZ), and (f) STAT3flox/flox/Cre (ASKO).  ASKO mice and WT and HZ littermate controls 
maintained on a mixed background were studied for further analysis.   
 
Animals and PCR genotyping 
  ASKO mice and littermate controls were housed 2-5 per cage in a temperature and 
humidity controlled pathogen-free facility, exposed to a 12 hour light/dark cycle, and fed a 
standard Purina rodent chow (LabDiet® ProLab Isopro RMH 3000, PMI Nutrition 
International, St. Louis, MO) and water ad libitum.  All protocols for animal use and 
euthanasia were reviewed and approved by the University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee. 
 
 Genotyping was performed by PCR amplification of genomic DNA isolated from tail 
tips of 3-4 week old mice.  The primers for identifying a floxed allele (5’ GCAAGACTGGA 
TGGCAAACCGCTATAACTT 3’and 5’ TCGGCAGGTCAATGGTATTGCTGCAGGTCG 
3’) amplify a 682 bp fragment.  The primers for identifying a wild-type allele (5’ AGGAAT 
AGGGAGGACATGGGGTGAGAGTTACCGTG 3’ and 5’ TCGGCAGGTCAATGGTATT 
GCTGCAGGTCG 3’) amplify a 262 bp fragment.  The primers for identifying the Cre 
transgene (5’ GCGGTCTGGCAGTAAAAACTATC 3’ and 5’GTGAAACAGCATTGCTGT 
CACTT 3’) amplify a 100 bp fragment.  To detect Cre-mediated recombination, primers 
were designed that are located on the loxP site (5’ GCAAGACTGGATGGCAAACCGCTA 
TAACTT 3’) and exon 23 (5’ TCGGCAGGTCAATGGTATTGCTGCAGGTCG 3’).  This 
primer pair gives rise to a 682 bp fragment or a 336 bp PCR fragment before and after Cre-
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mediated recombination respectively.  In all cases, PCR was performed using the 
GeneAmpPCR® Fast PCR Master Mix (Applied Biosystems, Foster City, CA).  PCR 
conditions were 94°C for 2 minutes, followed by 35 cycles of 94°C for 1 second and 64°C 
for 20 seconds.  A final extension step of 1 minute at 72°C was performed to ensure 
complete synthesis of all annealed products.   
 
Primary preadipocyte isolation and culture 
WAT was aseptically removed from male mice and stromal vascular cell cultures 
were established as previously described (169).  Briefly, WAT was excised from freshly 
killed ASKO mice and littermate controls. After excision, adipose tissue was minced into 
small pieces, washed in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
1% bovine serum albumin (BSA), and centrifuged at 1000 x g for 10 minutes to remove 
blood cells.  Tissue was then decanted into DMEM containing 1.0 mg/ml type I collagenase 
and digested for 45 minutes at 37ºC with constant end-over-end inversion.  Following the 
digestion, adipose cells and stromal vascular cells were separated by centrifugation at 500 x g 
for 10 minutes.  The stromal vascular cell pellet was resuspended and cultured in DMEM 
containing 10% v/v fetal bovine serum (FBS), 10 mg/ml streptomycin, 100 U/ml penicillin, 
and 1 mM pyruvate at 37°C in 5% CO2 air.  To induce differentiation, 2-day post-confluent 
preadipocytes were treated with Zen-Bio Differentiation Medium (Zen-Bio, Raleigh, NC). 
On day 3, the differentiation medium was replaced with Zen-Bio Adipocyte Maintenance 
Medium, which was changed every 2 days thereafter until analysis on day 8.  
  
 For analysis of lipolysis, on day 8, primary cells were incubated in the presence of 
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 vehicle, 1.0 µM isoproterenol, or recombinant leptin (R&D Systems, Minneapolis, MN), in 
doses ranging from 5.0 ng/ml to 100.0 ng/ml.  After twenty-four hours of incubation, 
glycerol released into the medium was measured using the Zen-Bio Adipocyte Lipolysis 
Assay Kit. 
 
Immunoblot analysis 
  Primary cells were washed twice in phosphate buffered saline with 1mM 
orthovanadate, and then placed immediately in sample buffer (1% NP40, 20 mM Tris-HCL 
(pH 8.0), 150 mM NaCl, 1mM EDTA, 0.1% NaN3, 10 µg/ml aprotinin, 1 µM pepstatin, 16.4 
µg/ml leupeptin, 1 mM phenylmethyl-sulfonylfluoride, 0.1 mM Na3VO4, 2% SDS, 10% 
glycerol).  Tissues were homogenized in sample buffer with a PRO Scientific PRO 200 
homogenizer (Oxford, CT).  Primary cell lysates, and heart, liver, kidney, hypothalamus, 
WAT, and brown adipose tissue (BAT) homogenates were heated and protein concentrations 
were determined using Bio-Rad Laboratories, Inc., DC protein determination kit (Richmond, 
CA).  BSA was used as a standard.  Samples were heated for 2 minutes at 85°C, separated by 
10% SDS-PAGE, and analyzed by immunoblotting.  Immunoblots were developed with the 
Pierce enhanced chemiluminescence kit (Rockford, IL).  
 
Dual Energy X-ray Absorptiometry (DEXA) measurement of body composition 
 Body composition was determined on anesthetized male mice using the Lunar 
PIXImus densitometer (GE Lunar Corporation, Madison, WI, USA).   
 
Indirect calorimetry 
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 Oxygen consumption (VO2), activity (horizontal, vertical, and ambulating), and food  
intake were measured using an Oxymax open-circuit indirect calorimetry system (Columbus 
Instruments International, Columbus, OH).  Male mice were placed in calorimeter chambers 
for 5 days in a light (12-hour light/dark cycle) and temperature controlled environment.  
Mice were maintained with free access to standard Purina rodent chow and water throughout 
the duration of the 5-day measurement period.  On day 5, lean mass was measured using the 
Lunar PIXImus densitometer.  Oxygen consumption and activity data are reported as the 
mean VO2 and mean counts of days 2-4 respectively.  Food intake data are reported as the 
mean daily intake of days 1-5. 
 
Biochemical assays   
 Blood was collected from cut tail tips of conscious male mice in either the fed or the 
fasting state.  Glucose was measured by the glucose oxidase method with a commercial 
glucometer (FreeStyle Flash Blood Glucose Monitoring System).  Blood was also obtained 
via retro-orbital sinus of anesthetized male mice in either the fed or the fasting state.  Plasma 
was collected in EDTA coated capillary tubes, and separated via centrifugation at 3000 x g 
for 10 minutes.  Plasma was used for measurement of insulin.  Serum was collected in plain 
capillary tubes, allowed to clot at room temperature for 20 minutes, and then separated via 
centrifugation at 3000 x g for 10 minutes.  Serum was used for measurement of leptin, 
adiponectin, TAG, and free fatty acids (FFAs).  Plasma insulin and serum leptin levels were 
measured by ELISA (Crystal Chem, Downers Grove, IL).  Serum adiponectin levels were 
measured by ELISA (R&D Systems, Minneapolis, MN).  Serum TAG was measured by 
colorimetric enzyme assay (Stanbio, Boerne, TX), and FFA levels in serum were measured 
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using the NEFA-kit-C (Wako Chemicals GmbH, Neuss, Germany).  Metabolic parameters 
measured in the fed state were in animals with free access to food assayed at 11:00 p.m.; for 
fasted-state measurements, mice were assayed at 8:00 a.m. after a 24 hour fast in a clean cage 
free of bedding.   
 
Glucose tolerance test 
 Oral glucose-tolerance tests were performed on male mice that did not have access to 
food for 4 hours before administration of 2.5 mg/g body weight glucose load by oral gavage.  
Glucose measurements were taken prior to oral gavage and 15, 30, 45, 60, 90, 120, and 150 
minutes after oral gavage.  To measure corresponding insulin levels, plasma was collected 
from cut tail tips prior to oral gavage and 15 and 30 minutes after oral gavage.       
 
Tissue TAG 
 The tissue lipid extraction procedure was adapted from methods previously described  
(170).  
 
Histology 
 Tissues from male mice were fixed in 10% phosphate-buffered paraformaldehyde, 
embedded in paraffin, and sectioned (5.0 µm) for hematoxylin/eosin staining.   
 
Quantitative real-time (TaqMan) RT-PCR          
WAT was removed from male mice and total RNA was isolated using the TRIzol 
method (Invitrogen, Carlsbad, CA).  1.0 µg RNA was reverse transcribed with the 
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Superscript II First Strand Synthesis kit (Invitrogen, Carlsbad, CA) using oligo (dT) primers.  
CCAAT/enhancer binding protein α (C/EBPα), peroxisome proliferators activated receptor γ 
(PPARγ), fatty acid binding protein (FABP2/aP2), leptin, adiponectin, FAS, diacylglycerol 
acyltransferase (DGAT), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA 
were quantified by real-time PCR using the Bio-Rad iCycler PCR machine (Hercules, CA).  
mRNA levels were normalized to GAPDH and presented as relative mRNA expression. 
Table 4.1  Primers and probes for real-time (TaqMan) RT-PCR.  
Gene Name Probe Primer pairs 
C/EBPα  5’-FAM-CAACAACATCGCGGTGCGCAAGAGCC-TAMRA-3’ 5’CAGCAACGAGTACCGGGTA3’ 
  5’TGCGTCTCCACGTTGCGTT3’ 
   
PPARγ  5’-FAM-TCCTGTCAAGATCGCCCTCGCCT-TAMRA-3’ 5’CATAAAGTCCTTCCCGCTGA3’ 
  5’TGACAAATGGTGATTTGTCCG3’ 
   
FABP2/aP2 5’-FAM-AATGGTCCAGGCCCCAGTGAGCT-TAMRA-3’ 5’TTCCCTACAGTCTAGCAGAC3’ 
  5’TCTACACGTGTGAATTTCCCA3’ 
   
Leptin  5’-FAM-CCGCCAAGCAGAGGGTCACTGG-TAMRA-3’ 5’ACATTTCACACACGCAGTCG3’ 
  5’TGAAGCCCAGGAATGAAGTC3’ 
   
Adiponectin  5’-FAM-CCGTGATGGCAGAGATGGCACTCCT-TAMRA-3’ 5’ATCCTGGCCACAATGGCACA3’ 
  5’CAAGAAGACCTGCATCTCCT3’ 
   
FAS 5’-FAM-TCCAGGTAAATGGGCCAGCCGAG-TAMRA-3’ 5’AGCTGTCCCCTGATGCCA3’ 
  5’GAGAACTCCATGCCGAGCA3’ 
   
DGAT 5’-FAM-CCACTGCGATCTCCTGCCACCTT-TAMRA-3’ 5’C TGTGCTCTACTTCACCT3’ 
  5’ACGGCCCAGTTTCGCA3’ 
   
GAPDH 5’-FAM-TGACTCCACTCACGGCAAATTCAACG-TAMRA-3’ 5’GCAGTGGCAAAAGTGGAGATTG3’ 
  5’CCATTCTCGGCCTTGCTGT3’ 
 
Statistical Analysis 
 All values are expressed as means ± SE.  An unpaired Student’s t test was used to 
assess statistical differences between ASKO mice and WT or HZ littermate controls.  A t test 
with a P value < 0.05 was considered statistically significant.   
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D.  RESULTS 
Generation of STAT3flox/+ mice. 
  To determine the role of STAT3 in adipogenesis and body weight homeostasis, we 
generated mice with an adipocyte-specific disruption of the STAT3 gene using aP2-Cre-loxP 
DNA recombination.  We constructed a STAT3 targeting vector with loxP sites flanking 
exon 22 of the murine STAT3 gene (Figure 4.1A).  Deletion of the loxP-flanked exon 22 by 
Cre recombinase was predicted to produce a truncated nonfunctional translational product 
missing a tyrosine residue (Tyr 705) essential for STAT3 activation (171).   
 
  The STAT3 targeting vector was linearized and electroporated into 129/SvEv 
embryonic stem (ES) cells (Figure 4.1B).  Gancyclovir and G418 resistant clones were 
screened for homologous recombination by PCR and Southern blot analysis.  Correctly 
targeted clones were transiently transfected with FlpE recombinase to delete neo (Figure 
4.1C).  Deletion of the selection cassette was confirmed by PCR and Southern blot analysis.  
Targeted ES cell clones devoid of neo were microinjected into C57BL/6 blastocysts, and 
mice carrying the floxed STAT3 allele (STAT3flox/+) were created as described in Materials 
and Methods.   
 
Creation of ASKO mice. 
  ASKO mice were generated by breeding mice heterozygous for the targeted STAT3 
gene (STAT3flox/+) and transgenic mice expressing Cre recombinase under the control of the 
adipocyte specific aP2 promoter/enhancer as described in Materials and Methods (Figure 
4.1D).  ASKO mice were obtained at the expected Mendelian frequency and exhibited  
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Targeted Allele
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LoxP                   FRT               FRT LoxP
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Figure 4.1 – Generation of ASKO mice.               
Schematic representation of (A) the STAT3 targeting vector, (B) the endogenous STAT3 
allele before (wild-type allele) and after (targeted allele) homologous recombination, (C) the 
targeted allele after FlpE recombination (functional allele), and (D) the functional allele after 
Cre-mediated deletion of exon 22 (knockout allele).                         
(E) Western blot analysis (IB) of STAT3 protein expression in heart, liver, kidney, 
hypothalamus, WAT, and BAT from WT, HZ, and ASKO mice. 
(F) Western blot analysis (IB) of STAT3 protein expression in subcutaneous primary 
preadipocytes isolated from WT, HZ, and ASKO mice 0, 2, 4, 6, and 8 days after induction 
of differentiation. 
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normal growth until the age of 9 weeks. 
 
  STAT3 expression was examined in tissue lysates from control and ASKO mice by 
Western blot analysis using an anti-STAT3 antibody which recognizes the C-terminal portion 
of the STAT3 protein.  STAT3 expression was preserved in the heart, liver, kidney, and 
hypothalamus of ASKO mice (Figure 4.1E).  By contrast, STAT3 expression was 
significantly reduced in WAT and brown adipose tissue (BAT) from ASKO mice (Figure 
4.1E).  The remaining STAT3 expression was likely derived from stromal vascular cells that 
did not express aP2.  STAT3 expression was not altered, however, in either WAT or BAT 
obtained from wild-type (WT) or aP2-Cre STAT3flox/+ (HZ) mice, suggesting that neither the 
loxP modification, nor expression of the aP2 transgene altered the expression of STAT3.  
These mice were considered controls.   
 
  The marked increase in aP2 expression during adipogenesis and the abundance of aP2 
mRNA and protein in mature adipocytes established aP2 as a late marker of adipocyte 
differentiation (56).  aP2 is also expressed in preadipocytes (172) and was recently identified 
as a marker for committed human preadipocytes (173).  To define the timing of Cre-mediated 
STAT3 deletion in ASKO mice, preadipocytes isolated from WT, HZ, and ASKO were 
differentiated in culture and lysates were recovered 0, 2, 4, 6, and 8 days after stimulation 
with differentiation medium. Western blot analysis revealed disappearance of STAT3 
expression beginning on day 6 of adipogenesis (Figure 4.1F). STAT3 expression in 
preadipocytes, however, was preserved, suggesting that the Cre transgene was sufficient to 
direct recombination only in mature adipocytes.  Therefore, ASKO mice and WT and HZ 
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  Figure 4.2 – Higher body weight and increased mass in ASKO mice.   
(A) Growth curves of male ASKO mice and WT and HZ littermate controls.  Data are means 
± SE (n = 8-16).  * Significantly different from WT and HZ littermate controls. 
(B) Lean mass, (C) fat mass, and (D) percent fat of 4-, 6-, 8-, 12-, and 16-week old male 
ASKO mice and WT and HZ littermate controls.  Data are means ± SE (n = 8-16).  
* Significantly different from WT and HZ littermate controls.    
(E) Representative PIXImus image of a 16-week old male ASKO mouse (left) and a 16-week 
WT control mouse (right). 
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 littermate controls were studied to establish the role of STAT3 in mature adipocytes. 
 
Higher body weight and increased adiposity in ASKO mice.   
  To determine the role of adipocyte STAT3 on body weight, ASKO mice and WT and 
HZ littermate control mice were weighed weekly.  Growth curves were normal in male and 
female ASKO mice from birth to 4 weeks of age.  Beginning at 9 weeks of age, however, 
male ASKO mice weighed significantly more than their littermate controls (Figure 4.2A).  
By 20 weeks of age, male ASKO mice had gained 14% and 16% more weight than their WT 
and HZ littermates, respectively.  Female growth curves, however, remained normal 
(supplemental data).  To determine the basis for the higher body weight in male ASKO mice, 
lean mass (Figure 2B), fat mass (Figure 4.2C), and percent fat (Figure 4.2D) were 
measured at 4, 6, 8, 12, and 16 weeks by Dual Energy X-ray Absorptiometry (DEXA).  Lean 
mass was similar between ASKO mice and littermate controls at all ages.  Fat mass and 
percent fat however, were increased in ASKO mice beginning at 6 weeks of age.  These 
differences were statistically significant by 16 weeks of age.  In addition, inguinal, gonadal, 
retroperitoneal, and interscapular brown fat pads from ASKO mice weighed significantly 
more than fat pads from littermate controls.  Significant differences were observed for both 
absolute fat pad weight (Figure 4.3B) and fat pad mass/g body weight (Figure 4.3D).  
Absolute liver weight was also significantly higher in male ASKO mice (Figure 4.3A).  
Liver weight/g body weight however, was indistinguishable, as were absolute heart weight, 
heart weight/g body weight, and absolute kidney weight.  Kidney weight/g body weight 
however, was significantly lower in ASKO mice.  These results indicate that the higher body 
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Figure 4.3 – Increased adiposity in ASKO mice.   
(A) Absolute organ weight, (B) absolute fat pad weight, (C) organ weight/g body weight, and 
(D) fat pad weight/g body weight in 20-week old male ASKO mice and 20-week old WT and 
HZ littermate controls.  Data are means ± SE (n = 8-12).   * Significantly different from WT 
and HZ littermate controls.  b Significantly different from HZ littermate controls.                        
(E) Hematoxylin and eosin staining of inguinal WAT, gonadal WAT, and retroperitoneal 
WAT, from 20-week old male ASKO mice and 20-week old WT littermate controls.                               
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Figure 4.4 – Normal gene expression in WAT from ASKO mice.   
Quantitative analysis of the expression levels of (A) PPARγ, C/EBPα, FABP2/aP2, (B) 
leptin, adiponectin, and (C) FAS and DGAT in WAT from 20-week old male ASKO mice 
and 20-week old WT littermate controls.  mRNA levels are normalized to GAPDH and 
presented as relative mRNA expression.  Data are means ± SE (n = 3-4). 
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 weight in male ASKO mice was due to increased adiposity.   
 
  Increased adiposity can result from an increase in adipocyte cell size (hypertrophy),  
an increase in adipocyte cell number (hyperplasia), or both.  To determine if adipocyte 
hypertrophy contributed to the increased adiposity in male ASKO mice, histological studies 
were carried out.  Histological analysis of WAT sections from WT and ASKO mice revealed 
that ASKO mice had larger adipocytes than WT mice, indicating that the increased adiposity 
in male ASKO mice was due to adipocyte hypertrophy (Figure 4.3E).   
 
  To determine if ASKO mice displayed changes in expression levels of adipogenic 
transcription factors and adipocyte-specific genes, gene expression analysis of WAT from 
WT and ASKO mice was conducted by real-time PCR.  RT-PCR revealed no differences in 
the expression of C/EBPα, PPARγ, and aP2 (Figure 4.4A).  WAT DNA content was also 
similar between WT and ASKO mice indicating that the increase in adipose tissue mass 
observed in male ASKO mice was not due to adipocyte hyperplasia (supplemental data).  
 
Normal food intake and energy expenditure in ASKO mice. 
  To determine if the increase in adiposity in male ASKO mice was due to positive 
energy balance, energy intake and energy expenditure were monitored in 12-week old ASKO 
mice and 12-week old WT littermate controls by an indirect calorimetry system as described 
in Materials and Methods.  Analysis of food intake showed no significant differences in 
absolute daily food intake (Figure 4.5A), or daily food intake/g body weight (Figure 4.5B) 
between ASKO mice and littermate controls.  As shown in Figure 4.5C and 4.5D, horizontal  
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Figure 4.5 – Normal food intake and energy expenditure in ASKO mice.   
(A) Absolute daily food intake and (B) daily food intake/g body weight in 12-week old male 
ASKO mice and 12-week old WT littermate controls.  Data are means ± SE (n = 8-11).                         
(C)  Horizontal activity (Xtot), ambulation (Xamb), and (D) vertical activity (Ztot) in 12-
week old ASKO mice and 12-week old WT littermate controls.  Data are means ± SE (n = 8-
11).                                                    
(E) O2 consumption (ml/kg body weight/hr) and (F) O2 consumption (ml/kg lean mass/hr) in 
12-week old male ASKO mice and 12-week old WT littermate controls.  Data are means ± 
SE (n = 8-11).   
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activity (Xtot), ambulation (Xamb), and vertical activity (Ztot) were also similar between 
ASKO mice and littermate controls.  Oxygen consumption normalized to body weight 
(Figure 4.5E) and lean body mass (Figure 4.5F) were also similar between ASKO mice and 
littermate controls.  These results indicate that the increased adiposity in male ASKO mice 
was not due to hyperphagia or reduced energy expenditure.  The methodology employed, 
however, may not be sensitive enough to detect subtle long term disturbances in energy 
balance.  Additionally, further studies are needed to determine if increased dietary fat 
absorption contributes to the higher body weight and increased adiposity.   
 
Normal glucose tolerance in ASKO mice. 
To determine the metabolic consequences of loss of adipocyte STAT3, we monitored 
circulating glucose, insulin, leptin, TAG, and FFAs in male ASKO mice and WT littermate 
controls at 12-16 weeks of age.  Under both fed and fasting conditions, no differences were 
observed in blood glucose levels or serum TAG or FFA levels between ASKO mice and WT 
mice (Table 4.2).  Fasting plasma insulin and serum leptin levels were also similar between 
ASKO and WT mice.  Because ASKO mice and WT mice had similar blood glucose and 
plasma insulin concentrations, we concluded that the increased adiposity in ASKO mice did 
not alter glucose homeostasis.  As expected, ASKO mice and WT mice exhibited comparable 
blood glucose concentrations at all time points after administration of an oral glucose load 
(Figure 4.6A).  Corresponding insulin levels (Figure 4.6B) were also similar.  In addition, 
the pancreas from ASKO mice exhibited no gross or histological abnormalities 
(supplemental data). 
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            Fasted                         Fed 
                                         
                                                              WT                   ASKO                 WT                  ASKO 
Blood glucose (mg/dL) 70.44 ± 4.06 70.0 ± 4.00 123.7 ± 10.52  123.0 ± 9.08  
Serum FFA (mEq/L) 1.06 ± 0.05 1.05 ± 0.04 0.28 ± 0.04 0.26 ± 0.03 
Serum TAG (mg/dL) 141.48 ± 7.14 133.96 ± 16.77 108.48 ± 3.75 108.83 ± 8.68 
Plasma Insulin (ng/mL) 0.82 ± 0.14 1.09 ± 0.27 ND ND 
     
Serum Leptin (ng/mL) 1.16 ± 0.26 1.30±0.46   
Serum Adiponectin (µg/mL) 7.32 ± 0.28 5.48 ± 0.22 *   
 
Table 4.2 – Normal biochemical parameters in ASKO mice. 
Biochemical parameters in 12-16 week old male ASKO mice and WT littermate controls.  
Data are means ± SE (n =6-10).   * Significantly different from WT and HZ littermate 
controls. 
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Figure 4.6 – Normal glucose tolerance and fatty liver in ASKO mice.   
(A) Blood glucose concentrations during oral glucose tolerance tests in 20-week old male 
ASKO mice and WT littermate controls.  Data are means ± SE (n = 8-11).                         
(B) Plasma insulin concentrations during oral glucose tolerance tests in 20-week old male 
ASKO mice and WT and HZ littermate controls.  Data are means ± SE (n = 6).                         
(C) Liver TAG content in 20-week old male ASKO mice and WT and HZ littermate controls.  
Data are means ± SE (n = 4-6).  b Significantly different from HZ mice.                       
(D) Hematoxylin and eosin staining of liver sections from 20-week old male ASKO mice and 
20-week old WT littermate controls. 
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Increased liver TAG in ASKO mice. 
 Fatty liver is strongly associated with both hepatic and adipose tissue insulin 
resistance, as well as reduced whole-body insulin sensitivity (174-176).  Because male 
ASKO mice exhibited normal glucose tolerance, as determined by oral glucose tolerance 
testing, we hypothesized that the increased adiposity was limited to the adipose tissue and did  
not affect the liver.  However, liver TAG was increased in ASKO mice (Figure 4.6C).  
Consistent with these data, histological analysis of liver sections from ASKO mice also 
showed a marked increase in lipid deposition (Figure 4.6D).  Furthermore, serum 
adiponectin levels, which correlate negatively with adiposity and hepatic fat (177, 178), were 
significantly reduced in ASKO mice (Table 4.2).   
 
Impaired leptin signaling in ASKO mice. 
The STAT3-activating ligand leptin induces weight loss, in part, via pro-lipolytic 
actions on adipose tissue (18-22, 24, 25, 179).  Additionally, leptinergic blockade, as 
demonstrated by a decrease in STAT3 tyrosine phosphorylation, protects diet-induced obese 
rodents from leptin’s fat depleting autocrine/paracrine actions (123).  To determine if loss of 
leptin action via disruption of STAT3 signaling was responsible for the increased adiposity in 
male ASKO mice, leptin-induced lipolysis studies were carried out in adipocytes 
differentiated in culture from preadipocytes isolated from WT and ASKO mice.  Eight days 
after differentiation, WT and ASKO cells were stimulated with varying doses of recombinant 
leptin (rLeptin).  Glycerol released into the medium was measured after 24 hours of leptin 
exposure.  The addition of rLeptin to WT cells promoted glycerol release relative to cells 
treated with vehicle alone (Figure 4.7A).  The addition of rLeptin to ASKO cells, however,  
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Figure 4.7 – Impaired leptin signaling in ASKO mice. 
(A) Glycerol released from WT and ASKO cells stimulated with varying doses of 
recombinant leptin (rLeptin) or isoproterenol.  Data are means ± SE from triplicate dishes 
repeated three times. 
(B) Western blot analysis (IB) of STAT1 tyrosine phosphorylation in subcutaneous primary 
preadipocytes isolated from WT and ASKO mice cultured in the presence of 10.0ng/ml 
rLeptin for twenty-four hours. 
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had no effect (Figure 4.7A); suggesting that adipocyte STAT3 mediates leptin-induced 
lipolysis.  Isoproterenol-induced lipolysis, however, was unimpaired in ASKO cells (Figure 
4.7A).  In addition, an increase in STAT1 tyrosine phosphorylation was observed only in 
ASKO cells exposed to rLeptin (Figure 4.7B).   
 
Leptin also induces weight loss via anti-lipogenic actions on adipose tissue (18-22, 
24, 25, 179).  To determine if loss of leptin’s anti-lipogenic actions was responsible for the 
increased adiposity in male ASKO mice, we examined the expression of lipogenic genes.  
Gene expression analysis of WAT from WT and ASKO mice revealed no differences in the 
expression of FAS or diacylglycerol acyltransferase (DGAT) (Figure 4.4C).   
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E.  DISCUSSION 
In the present studies we show that ASKO mice fed a standard chow diet weigh more 
than their littermate controls and demonstrate that the higher body weight is due to increased 
adiposity associated with adipocyte hypertrophy, but not adipocyte hyperplasia, hyperphagia, 
or reduced energy expenditure.  The higher body weight and increased fat mass exhibited by 
ASKO mice in this study are in agreement with other tissue-specific STAT3 knockout 
models linking STAT3 and adiposity (89-91).  Mice with a neural-specific disruption of the 
STAT3 gene are obese, hyperleptinemic, leptin resistant, diabetic, and infertile.  Mice with a 
β cell/hypothalamic specific-disruption of the STAT3 gene are also obese, hyperphagic, 
hyperglycemic, and hyperinsulinemic.  In contrast, ASKO mice are obese but are not 
hyperphagic and do not develop insulin resistance.  In addition, phenotypic changes are 
observed in male ASKO mice only.  While the mechanisms causing these sex differences are 
unknown, they may reflect alternative pathways compensating for the lack of STAT3 in 
female mice.  Recent studies showing that aromatase-deficient mice have a phenotype of 
increased adiposity (180) suggest that estrogen signaling pathways may have a compensatory 
effect on STAT3 deficiency in female ASKO mice. 
 
Because increased fat mass in ASKO mice was accompanied by adipocyte 
hypertrophy without changes in cell number or differentiation, we concluded that increased 
fat mass was the result of increased TAG accumulation in preexisting adipocytes.  We 
hypothesized that the cause of the enhanced TAG accumulation was either increased fatty 
acid and TAG synthesis or decreased TAG breakdown.  Because the STAT3-activating 
ligand leptin has been shown to have both anti-lipogenic and pro-lipolytic actions in adipose 
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tissue (18-22, 179), we speculated that loss of leptin action was responsible for the increased 
TAG accumulation in adipocytes from ASKO mice.  We found that leptin-induced lipolysis 
was impaired in adipocytes differentiated in culture from preadipocytes isolated from ASKO 
mice.  Isoproterenol-induced lipolysis, however, was unimpaired in ASKO cells, suggesting 
that leptin-induced lipolysis is dependent on STAT3, but not lipolysis induced by adrenergic 
stimulation.  Because STAT1 was tyrosine phosphorylated in ASKO cells but not in WT 
cells cultured in the presence of rLeptin, STAT1 is likely not used as an alternative pathway 
in leptin-induced lipolysis.  As for fatty acid and TAG synthesis, the expression of lipogenic 
genes was increased in ASKO WAT, but not to a significant degree.  Because mRNA levels 
do not always correlate with enzyme activity, further studies examining the activity of 
lipogenic enzymes are needed to better understand the mechanism of TAG accumulation in 
adipocytes from ASKO mice.   
 
 Recent studies have shown a relationship between adipocyte size and adipokine 
expression and secretion.  Serum adiponectin levels, for example, correlate inversely with 
adipocyte size (181, 182), while serum leptin levels correlate positively (183).  In agreement 
with the significant hypertrophy of adipocytes in ASKO mice, serum adiponectin levels were 
significantly reduced.  Serum leptin levels, however, were not increased.  There are several 
possible explanations for this finding.  The increase in WAT TAG content may not have been 
sufficient to trigger an increase in leptin synthesis.  Furthermore, altered adipocyte 
differentiation is frequently associated with changes in circulating leptin levels (64, 184, 
185).  Response elements for adipogenic transcription factors and adipocyte-specific genes 
have also been identified in the leptin promoter (186).  The absence of adipocyte hyperplasia 
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in ASKO mice, therefore, was consistent with the lack of increased serum leptin levels.  
Additionally, it has been shown that circulating FFAs stimulate leptin secretion (179, 187).  
Thus, the absence of increased serum FFAs in ASKO mice was also consistent with the 
observed normal circulating leptin levels.   
 
 Because ASKO mice developed a fatty liver, however, it is notable that they did not 
exhibit elevated FFAs.  The fact that serum fatty acids were not increased in these animals 
suggests that an increased supply of fatty acids to the liver was not the cause of the steatosis.  
Rather, an imbalance in liver TAG synthesis, export, or oxidation was likely the cause.  It has 
been shown that high adiponectin levels protect against fatty liver by reducing fatty acid 
synthesis through inhibition of acetyl-CoA carboxylase (ACC) and FAS expression and 
activity (188).  The reduction of ACC activity also reduces the malonyl CoA level, which is 
known to inhibit carnitine palmitoyltransferase I (CPT-1) activity and fatty acid oxidation.  
Therefore, we speculate that the reduced serum adiponectin levels in ASKO mice likely 
increased fatty acid synthesis and reduced fatty acid oxidation thus causing the fatty liver.  
Further studies examining changes in gene expression and enzyme activity are needed to 
understand the exact cause of the TAG accumulation in the livers of ASKO mice. 
 
It is also notable that while ASKO mice are obese and develop a fatty liver, they 
exhibit normal glucose tolerance on a standard chow diet.  The ASKO mouse model is not 
the only mouse model in which obesity is dissociated from impaired glucose tolerance.  Mice 
lacking AMP-activated protein kinase-α2 (AMPKα2) exhibit increased adiposity and 
adipocyte hypertrophy, but show no differences in glucose tolerance or insulin sensitivity 
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compared to WT mice (189).  Mice that overexpress phosphoenolpyruvate carboxykinase 
(PEPCK) in WAT also have increased adipose tissue mass but do not develop insulin 
resistance (190).  Similarly, mice that overexpress DGAT-1 in WAT have larger adipocytes 
and greater total fat pad weight.  The increased adiposity, however, is not associated with 
impaired glucose disposal (191).  Finally, obesity is dissociated from insulin resistance in 
aP2 deficient mice fed a high fat diet (192).  We cannot rule out the possibility, however, that 
with age or following a long-term challenge with a high fat diet, ASKO mice may develop 
insulin resistance.  Furthermore, as fat accumulation in the liver is a primary event leading to 
insulin resistance (193-195), it is also possible that as the severity of the fatty liver worsens, 
ASKO mice may develop insulin resistance as well. 
 
  In summary, here we show that loss of STAT3 in mature adipocytes causes higher 
body weight, increased adiposity associated with adipocyte hypertrophy, reduced serum 
adiponectin levels, and fatty liver, but not impaired glucose tolerance.  We also show that 
loss of leptin action in WAT, namely loss of leptin-induced lipolysis, may play a role in the 
observed obese phenotype.  The results of our study clearly demonstrate that STAT3 is 
essential for body weight homeostasis, though further studies are needed to better clarify its 
role in this regard, especially as it relates to the development of obesity in ASKO mice. 
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Figure 4.8 – Supplemental data 
(A) Growth curves of female ASKO mice and WT and HZ littermate controls.  Data are 
means ± SE (n = 8-16).  
(B)  Total DNA content in WAT from male ASKO mice and WT littermate controls.  Data 
are means  ± SE (n = 6).     
(C) Hematoxylin and eosin staining of pancreas sections from 20-week old male ASKO mice 
and 20-week old male WT littermate controls. 
88 
CHAPTER V 
SYNTHESIS 
 
A.  OVERVIEW OF RESEARCH FINDINGS 
 This dissertation describes two independent projects that examined the function and 
activation of STAT3 in adipogenesis and adipocyte metabolism.  This work sought to 
improve our understanding of preadipocyte proliferation, differentiation, and metabolism, as 
well as the contribution of STAT3 and STAT3 signaling pathways to these processes.  The 
first project identified the differentiation-induced STAT3 activating factor and determined its 
role in adipogenesis.  The aim of the second project was to determine the role of STAT3 in 
adipogenesis in animals.  Mice with an adipocyte-specific disruption of the STAT3 gene 
(ASKO mice), created using aP2-Cre-loxP DNA recombination, and primary preadipocytes 
isolated from ASKO mice, were used for this project.  This section briefly summarizes this 
research and provides a synthesis of our findings.   
 
1.  Midkine is an Autocrine Activator of STAT3 in 3T3-L1 Cells   
Our project examining the mechanism of STAT3 tyrosine phosphorylation during 
adipogenesis was prompted by our initial observation that STAT3 activation during 
adipogenesis was delayed.  These results suggested that a mechanism other than direct 
activation by MDI was involved.  In subsequent studies using conditioned medium (CM), we 
confirmed that an autocrine/paracrine factor, synthesized and released in response to MDI, 
activated STAT3.  Based on a series of experiments showing that 1) midkine was expressed
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in 3T3-L1 preadipocytes,  2) midkine induced STAT3 tyrosine phosphorylation in a time- 
and dose-dependent manner, and 3) midkine neutralizing antibodies inhibited CM-induce 
STAT3 tyrosine phosphorylation, we concluded that the heparin-binding growth factor 
midkine was the autocrine/paracrine activator of STAT3 in 3T3-L1 cells.     
 
 Next we found that midkine was sufficient to stimulate post-confluent preadipocyte 
proliferation, likely though a STAT3 signaling pathway.  Although mitotic clonal expansion 
is required from progression through the differentiation program (37, 39, 40), we found that 
midkine was not sufficient to induce differentiation in the absence of MDI.  Midkine was 
necessary, however, for adipogenesis.  Cells treated with MDI plus anti-midkine antibody 
accumulated significantly less TAG than cells treated with MDI alone.  The expression of 
adipogenic transcription factors was also significantly reduced in cells treated with MDI plus 
anti-midkine antibody.  We concluded, therefore, that the midkine/STAT3 signaling pathway 
is necessary for mitotic clonal expansion and differentiation.  This work supports our initial 
hypothesis and highlights the midkine/STAT3 signaling pathway as a potential 
pharmaceutical target for the treatment of obesity.   
 
This was the first study to show that the heparin-binding growth factor midkine is 
sufficient for mitotic clonal expansion.  This finding parallels previous studies linking 
adipocyte hyperplasia to an augmented production of heparin-binding growth factors (160).  
Similarly to midkine, these mitogens have been shown promote preadipocyte proliferation 
via autocrine/paracrine mechanisms (166).  Although these studies suggest that midkine may 
contribute to the increased cellularity associated with severe obesity, continued research is 
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needed.  Transgenic mice overexpressing midkine selectively in WAT would provide a 
physiological model to study the role of midkine in the development of adipocyte 
hyperplasia. 
 
Another limitation of this study was the lack of a sensitive method to detect midkine 
protein in the CM.  Continued research is also needed, therefore, to determine if midkine is 
released by preadipocytes, and if midkine expression and plasma concentrations are 
increased in models of obesity. 
 
2.  Adipocyte-Specific Disruption of Signal Transducer and Activator of Transcription  
3 (STAT3) Increases Body Weight and Adiposity 
 Our first project identified a midkine-STAT3 signaling pathway that is necessary for 
adipogenesis.  The aim of our second project was to build on this finding and determine the 
physiological role of STAT3 in adipogenesis using mice with an adipocyte-specific 
disruption of the STAT3 gene.  Because the midkine-STAT3 signaling pathway was 
necessary for adipogenesis in vitro, we hypothesized that mice lacking adipocyte STAT3 
would have dramatically reduced amounts of WAT and exhibit physiological consequences 
associated with lipoatrophy.  In practice, however, STAT3 expression was preserved in 
preadipocytes limiting us from examining the physiological role of STAT3 in adipogenesis.  
Consequently, this mouse model was studied to determine the role of STAT3 in the mature 
adipocyte. 
  
 In this project, we found that male ASKO mice weighed significantly more than their  
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littermate controls and concluded that their higher body weight was due to increased 
adiposity accompanied by adipocyte hypertrophy without changes in cell number, food 
intake, or energy expenditure.  We also found that increased adiposity was not restricted to 
adipose tissue.  Liver TAG was increased in male ASKO mice as well.  Furthermore, serum 
adiponectin levels, which correlate negatively with adiposity and hepatic fat (177, 196), were 
significantly reduced.   Surprisingly, despite increased fat mass and liver TAG, male ASKO 
mice displayed normal glucose tolerance, and normal circulating insulin, leptin, TAG, and 
FFAs.  We also found that leptin signaling in WAT was impaired in ASKO mice.  Based on 
these findings, we concluded that STAT3 plays an essential role in body weight homeostasis.  
This work is in agreement with other studies linking STAT3 and adiposity (89-91), and 
highlights the importance of STAT3 in adipocyte metabolism.   
 
 One limitation of this study was the lack of a definitive mechanism to explain the 
ASKO phenotype.  This raises several interesting questions:  What is the mechanism of the 
fatty liver in ASKO mice?  Is obesity dissociated from insulin resistance in the ASKO mouse 
model?  Is loss of leptin, IL-6 and/or CNTF’s anti-lipogenic and pro-lipolytic actions on 
adipocytes responsible for the obese phenotype in ASKO mice?  Continued research is 
needed to answer these pressing questions.  
 
B.  DIRECTIONS FOR FUTURE RESEARCH 
The research presented here could proceed in many natural directions that will 
contribute to the understanding of preadipocyte proliferation, differentiation, and 
metabolism, as well as the contribution of STAT3 and STAT3 signaling pathways to these 
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processes.  In addition to studying the in vivo contribution of midkine to adipocyte 
hyperplasia and obesity, continued research is needed to better clarify the observed 
phenotype in ASKO mice.  This work could help to direct efforts to identify potential 
adipose-tissue driven causes of human obesity and to discover targets for the treatment of 
diseases such as obesity, hepatic steatosis, and insulin resistance.   
 
1.  Adiponectin and fatty liver disease in ASKO mice  
In “Adipocyte-Specific Disruption of Signal Transducer and Activator of 
Transcription 3 (STAT3) Increases Body Weight and Adiposity”, we found that liver TAG 
content was significantly increased in ASKO mice, and concluded that an imbalance in liver 
TAG synthesis, export, and oxidation likely caused the fatty liver.  Because high adiponectin 
levels protect against fatty liver by reducing TAG synthesis and increasing fatty acid 
oxidation (188), we hypothesized that reduced adiponectin levels in ASKO mice were 
responsible for the steatosis.  Additional studies are needed, however to determine the 
mechanism of the fatty liver. 
 
To characterize the impact of low adiponectin levels on fatty liver in ASKO mice, 
future studies will examine the expression and activity of genes involved in TAG synthesis 
and oxidation.  Further studies will also examine the effect of chronic adiponectin 
administration on gene expression, enzyme activity, and liver TAG content.  If decreased 
adiponectin levels are the cause of the liver TAG accumulation, we expect ACC and FAS 
expression and activity to be increased in livers from ASKO mice, and CPT-1 activity to be 
decreased in livers from ASKO mice.  In contrast, we expect continuous administration of 
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adiponectin to significantly decrease ACC and FAS expression and activity, significantly 
increase CTP-1 activity, and as a result, dramatically reduce hepatic lipid content. 
 
2.  Evidence for a causal relationship between hepatic steatosis and insulin resistance in 
ASKO mice 
Although hepatic steatosis and insulin resistance co-exist in many rodent models of 
obesity (174-176), whether insulin resistance is the cause or the effect of hepatic steatosis 
remains unclear.  Savage et al. suggest that increases in liver diacylglycerol, due to increased 
lipogenesis and/or decreased fatty acid oxidation, activate PKC-ε, which binds to and 
inactivates the insulin receptor, resulting in reduced IRS-1 and IRS-2 tyrosine 
phosphorylation.  This in turn results in reduced insulin activation of P13-kinase and AKT, 
resulting in lower insulin-stimulated liver glycogen synthesis and decreased suppression of 
hepatic gluconeogenesis (197). 
 
As discussed in “Adipocyte-Specific Disruption of Signal Transducer and Activator 
of Transcription 3 (STAT3) Increases Body Weight and Adiposity”, while ASKO mice are 
obese and develop a fatty liver, they exhibit normal glucose tolerance.  As the severity of the 
fatty liver worsens, however, it is possible that ASKO mice will develop insulin resistance. 
The ASKO mouse model, therefore, provides a perfect model for determining if a causal 
relationship exists between hepatic steatosis and insulin resistance. 
 
To characterize the impact of fatty liver on insulin resistance, glucose homeostasis 
studies will be performed on aged ASKO mice.  Glucose homeostasis studies will also be 
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performed on ASKO mice following a long-term challenge with a high fat diet.  In aged 
mice, we expect the severity of the fatty liver to worsen.  We also expect the severity of the 
fatty liver to worsen in ASKO mice on a high fat diet.  If a causal relationship exists between 
hepatic steatosis and insulin resistance, we also expect aged ASKO mice and ASKO mice on 
a high fat diet to develop insulin resistance.  
 
3.  Mechanism for the obese phenotype in ASKO mice  
  In “Adipocyte-Specific Disruption of Signal Transducer and Activator of 
Transcription 3 (STAT3) Increases Body Weight and Adiposity”, we found that increased fat 
mass in ASKO mice was the result of increased TAG accumulation in preexisting adipocytes.  
We hypothesized that the cause of the enhanced TAG accumulation was increased fatty acid 
and TAG synthesis and/or decreased TAG breakdown due to loss of leptin, IL-6 and/or 
CNTF’s anti-lipogenic and pro-lipolytic actions on adipocytes via disruption of STAT3 
signaling.  Although we found that leptin-induced lipolysis was impaired ex vivo, additional 
studies are needed to characterize the impact of loss of leptin, IL-6, and CNTF action on the 
obese phenotype in ASKO mice.   
  
 To answer these questions, WT and ASKO primary cells will be labeled with [14C]  
oleate after stimulation with recombinant leptin, IL-6, or CNTF.  Following stimulation, lipid 
extracts from cells and media will be separated by thin layer chromatography, and fatty acid 
incorporation into synthetic and oxidative pathways will be quantified.  Because leptin, IL-6 
and CNTF have anti-lipogenic and pro-lipolytic and oxidative actions on adipose tissue, we 
expect fatty acids to be channeled towards oxidative pathways and away from synthetic 
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pathways in WT cells.  Alternatively, if STAT3 mediates the anti-lipogenic and pro-lipolytic 
and oxidative actions of leptin, IL-6 and CNTF, we expect fatty acids to be channeled 
towards synthetic pathways and away from oxidative pathways in ASKO cells.   
  
To further clarify the impact of loss of leptin, IL-6, and CNTF action on the obese 
phenotype in ASKO mice, a wild-type recipient mouse will be transplanted with a fat pad 
resected from a wild-type donor mouse and a fat pad resected from an ASKO donor mouse.  
In addition, an ASKO recipient mouse will be transplanted with a fat pad resected from an 
ASKO donor mouse and a fat pad resected from a wild-type donor mouse.  After the surgery, 
hyperleptinemia will be induced in the recipient mice.  To determine if loss of IL-6 or CNTF 
action is responsible for the increased TAG accumulation in adipocytes from ASKO mice, 
similar experiments will be performed.  If STAT3 mediates the fat depleting autocrine 
actions of leptin, IL-6, and CNTF, we expect that WT recipients will lose more body weight 
than ASKO recipients.  Furthermore, we expect that fat will be depleted from native wild-
type fat pads and fat pad transplants from wild-type mice, but not from native ASKO fat pads 
or fat pad transplants from ASKO mice.  Therefore, we expect that WT recipients will also 
lose more fat mass than ASKO recipients. 
 
4.  A new model of STAT3 deficiency 
 In “Midkine is an Autocrine Activator of STAT3 in 3T3-L1 Cells” we identified a 
midkine-STAT3 signaling pathway that was necessary for preadipocyte mitotic clonal 
expansion and differentiation.  In view of this finding, in “Adipocyte-Specific Disruption of 
Signal Transducer and Activator of Transcription 3 (STAT3) Increases Body Weight and 
96 
Adiposity”, we set out to determine the role of STAT3 in adipogenesis in animals.  Because 
aP2-Cre driven deletion of STAT3 did not occur until late in the adipogenic program, the 
effect of loss of STAT3 on adipogenesis could not be assessed in this knockout model.  
Consequently, to characterize the impact of STAT3 deficiency on adipocyte formation, a new 
knockout model is needed.   
 
 To create this knockout model, mice heterozygous for the targeted STAT3 gene 
(STAT3flox/+) will be crossed with transgenic mice expressing Cre recombinase under the 
control of a preadipocyte specific promoter such as Pref-1.  If STAT3 is necessary for 
preadipocyte proliferation and differentiation, we expect that mice lacking preadipocyte 
STAT3 will have dramatically reduced amounts of WAT and exhibit physiological 
consequences associated with lipoatrophy.  Alternatively, using 3T3-L1 preadipocyte and 
RNAi, we will establish a STAT3 knockout cell line.  If STAT3 is necessary for 
preadipocyte proliferation and differentiation in this model, we expect that STAT3-/- cells 
will neither undergo mitotic clonal expansion nor differentiate into adipocytes.  
 
C.  PUBLIC HEALTH SIGNIFICANE 
 The prevalence of obesity, the host of co-morbidities associated with the disease, as 
well as the economic impact of the disease, make obesity a significant public health concern.  
The costs associated with cancer detection and treatment, as well as the prevalence and high 
mortality rates of the disease also highlight cancer as a serious public health issue.  
Therefore, given that our findings may facilitate the development of anti-obesity drugs and 
cancer therapies, this work clearly has important implications for advancing public health 
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 and generating new avenues for future research.    
  
For example, our studies identifying a midkine-STAT3 signaling pathway in 
proliferating preadipocytes that is necessary for adipogenesis revealed new targets for the 
pharmacological treatment of obesity.  Drugs designed to target this signaling pathway, 
particularly by inhibiting midkine or STAT3 expression, or by inhibiting STAT3 tyrosine 
phosphorylation, dimerization, or DNA binding, may promote weight loss by blocking 
adipogenesis.  Furthermore, our studies establishing that adipocyte STAT3 regulates body 
weight homeostasis revealed an alternative means to target obesity via STAT3.  By activating 
lipolytic pathways and inhibiting lipogenic pathways, pharmacological agents designed to 
target adipocyte STAT3 may also promote weight loss.   
 
Additionally, because midkine is overexpressed in a variety of cancers (150-155, 
165), and because constitutively active STAT3 has been observed in a variety of cancer cell 
lines and primary tumors (101-105), midkine and STAT3 may also serve as targets for the 
treatment of cancer.  By promoting apoptosis and preventing proliferation, drugs designed to 
inhibit midkine or STAT3 expression, or block STAT3 tyrosine phosphorylation, 
dimerization or DNA binding, may serve to suppress tumor growth.   
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CHAPTER VI 
DETAILED METHODS 
 
A.  ANIMAL MODELS 
 To determine the role of STAT3 in adipocyte formation and body weight 
homeostasis, using the Cre-loxP DNA recombination system, we generated mice with an 
adipocyte-specific disruption of the STAT3 gene (ASKO mice).  Conditional gene 
inactivation involved six steps (Figure 6.1):   
1.  Assembly of the targeting vector 
2.  Production and identification of targeted embryonic stem (ES) cell clones 
3.  Removal of the positive selection marker by FlpE recombinase 
4.  Production of chimeras by blastocyst injection of targeted ES cells 
5.  Transmission of the functional allele through the mouse germline 
6.  Inactivation of the functional allele by Cre recombinase 
 
1.  Assembly of the Targeting Vector 
 A targeting vector is designed to recombine with a specific chromosomal locus.  The 
essential components of such a vector are a plasmid backbone and sequences which are 
homologous with the desired chromosomal integration site.  
 
1.1  The OSfrt-loxP Plasmid  
 The OSfrt-loxP plasmid (kindly provided by Oliver Smithies and the Animal Models 
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 Core and the University of North Carolina at Chapel Hill) served as the plasmid backbone 
for the STAT3 targeting vector.  This OSfrt-loxP plasmid has several unique features 
including a positive selection marker and a negative selection marker, FRT sites flanking the 
positive selection marker to facilitate its removal by FlpE recombinase, a loxP site to 
facilitate removal of the targeted exon by Cre recombinase, and five unique restriction sites, 
SpeI, AgeI, XhoI, BamHI, and SalI (Figure 6.2). 
 
1.1.1  Positive-Negative Selection   
 Because the transfection efficiency and targeting frequency of targeting vectors are 
low, it is desirable to include both positive and negative selection makers.  Positive selection 
markers are included in the targeting vector to facilitate the isolation of ES cell clones that 
incorporate the targeting vector by homologous recombination.  The OSfrt-loxP plasmid 
relies on the neomycin phosphotransferase (neo) gene for positive selection.  Neo confers 
resistance to G418.  Therefore, because neo is included within the regions of homology, 
clones carrying the desired homologous recombination event are G418 resistant and survive.  
Clones in which the construct integrates randomly, however, are also resistant to G418 and 
survive.  To facilitate the elimination of these randomly integrated ES cell clones, a negative 
selection marker is also included in the targeting vector.  The OSfrt-loxP plasmid relies on 
the thymidine kinase (TK) gene for negative selection.  TK is included outside the regions of 
homology.  Because sequences outside the regions of homology are lost during homologous 
recombination, ES cell clones carrying the desired homologous recombination event do not 
retain the TK gene.  During random integration however, all sequences in the construct are 
retained.  Thus, random integrants retain the TK gene.  In the presence of the TK gene, cells 
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are sensitive to gancyclovir.  Therefore, homologous recombinants are gancyclovir resistant 
and survive, whereas the majority of clones in which the construct integrates randomly are 
gancyclovir sensitive and die.     
 
1.1.2 Site-Specific Recombinase Systems:  Cre-loxP and FlpE-FRT  
 Site-specific recombination systems are comprised of two elements:  the recombinase 
enzyme and DNA sequences recognized by the recombinase enzyme.  The target sites for 
two recombinase systems, the Cre-loxP system from the bacteriophage P1 and the FlpE-FRT 
system from the budding yeast Saccharomyces cerevisiae, are key components of the OSfrt-
loxP plasmid.  The loxP (locus of cross-over (x) in P1) site is included in the targeting vector 
to facilitate removal of the targeted exon by Cre recombinase.  FRT sites are included to 
facilitate neo removal by FlpE recombinase. 
  
 The target sites for both Cre recombinase and FlpE recombinase are 34 base pairs.  
These sites consist of 13 base pair repeats flanking an 8 base pair A:T-rich asymmetric core.  
The 13 base pair repeats provide binding sites for the recombinase enzyme.  The core 
sequence is the site of strand cleavage, exchange, and ligation.  Furthermore, the orientation 
of the target sites, relative to each other, determines the type of modification catalyzed by the 
recombinase enzyme.  Directly oriented sites, as included in the OSfrt-loxP plasmid, lead to 
excision of intervening DNA.   
 
1.2. Homologous Sequences  
 Because the STAT3 gene was the desired chromosomal integration site, the murine 
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 STAT3 gene was amplified by PCR (Figure 6.3) and cloned into the OSfrt-loxP plasmid 
(Figure 6.4A).  To increase the targeting frequency, the homologous sequences were derived 
from genomic DNA isogenic with the ES cells to be used in the targeting experiment (See 
Section 2. Production and Identification of Targeted ES Cell Clones).  First, the long arm of 
homology was amplified from 129/SvEv genomic DNA using the LAStatF 
(5’ACTAGTTCAGAGTCTCAGCACTCACTCCAC3’) and LAStatR (5’ACCGGTTTGCCATCCAG 
TCTTGCAGTTTGAAGTTCT3’) primers.  The resulting 3.3kb PCR product spanned exon 21 
of the STAT3 gene.  For cloning purposes, a SpeI restriction site and an AgeI restriction site 
were introduced at the 5’end and the 3’ end of the fragment respectively.  Next, the short arm 
of homology was amplified utilizing 129/SvEv genomic DNA and the SAStatF 
(5’GGATCCTGAAGGGCTGGTAGCTGCTGGGCTTGTTTA3’) and SAStatR (5’GTCGACCTCAG 
TGTTCCAGTAAGCTGAGTGAGCGAA3’) primers.  The resulting 2.4kb PCR product spanned 
exons 23 and 24 of the STAT3 gene.  For cloning purposes, a BamHI restriction site and a 
SalI restriction site were introduced at the 5’end and the 3’ end of the fragment respectively.  
Finally, the target arm was amplified utilizing 129/SvEv genomic DNA and the E22StatF 
(5’ACCGGTATAACTTCGTATAGCATACATTATACGAAGTTATGCAGCATGTGATGAGGGAGG
ACAGCCCTAA3’) and E22StatR (5’CTCGAGCGGTAACTCTCACCCCATGTCCTCCCTATT3’) 
primers.  The resulting 339bp PCR product spanned exon 22 of the STAT3 gene and 
included a tyrosine residue necessary for STAT3 activation.  A loxP site was introduced 
upstream of exon 22 (to facilitate removal by the Cre recombinase).  For cloning purposes, 
an AgeI restriction site and a XhoI restriction site were introduced at the 5’end and the 3’ end 
of the fragment respectively. 
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Next, the long arm, short arm, and target arm were cloned into the OSfrt-loxP 
plasmid at the SpeI and AgeI restriction sites, the BamHI and SalI restriction sites, and the 
AgeI and XhoI restriction sites of the OSfrt-loxP plasmid respectively.  A series of diagnostic 
digests (Figure 6.4B) and sequencing experiments were performed to confirm proper 
assembly of the targeting vector. 
 
2.  Production and Identification of Targeted ES Cell Clones  
 Next, 20.0µg of the assembled STAT3 targeting vector was electroporated into 2 x 
107 129/SvEv pluripotent ES cells.  When a targeting vector is electroporated into ES cells, 
the targeting vector can either integrate into its target locus or it can integrate into a random 
chromosomal location.  To identify ES cell clones carrying the desired homologous 
recombination event, ES cell were grown in the presence of gancyclovir and G418.  
Gancyclovir and G418 resistant clones were then screened for homologous recombination by 
PCR (Figure 6.5).  ES cell clones carrying the desired homologous recombination event (as 
identified by PCR) were expanded.  Homologous recombination was then confirmed in these 
clones by Southern blot analysis (Figure 6.6). 
 
3.  Removal of Neo by FlpE Recombinase  
 As previously mentioned, the positive selection marker is a necessary component of 
the targeting vector because it facilitates the isolation of ES cell clones that stably incorporate 
the targeting vector.  If retained however, it can interfere with the target locus and other 
genes linked to the target locus (198, 199).  Therefore, to eliminate these undesirable effects, 
it is necessary to remove the positive selection marker following gene targeting.     
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 Neo removal was accomplished with the use of the FlpE-FRT site-specific 
recombination system.  Targeted clones were electroporated with a vector that transiently 
expressed FlpE recombinase (kindly provided by the Animal Models Core at the University 
of North Carolina at Chapel Hill).  Clones were then screened for neo removal by PCR 
(Figure 6.7). 
 
4.  Production of Chimeras by Blastocyst Injection of Targeted ES Cells  
 Next, 129/SvEv targeted ES cell clones not containing neo were microinjected into 
blastocysts derived from superovulated C57BL/6 females (Figure 6.8).  To generate mice 
chimeric from the targeted ES cells and host blastocysts, microinjected blastocysts were 
transferred to the uterus of pseudopregnant C57BL/6 recipients.  Mice were rendered 
pseudopregnant through matings with vasectomized males during ovulation.     
 
5.  Transmission of the Functional Allele through the Mouse Germline  
 Because germ cells are derived from the same cell lineage that gives rise to the skin 
(primitive ectoderm), coat color was used to estimate the degree of germline contribution of 
the targeted ES cells.  As previously mentioned, the blastocysts used to generate the chimeric 
mice were derived from C57BL/6 females, which have a black coat.  Furthermore, the 
targeted ES cells that were implanted into the blastocysts were derived from the 129/SvEv 
substrain, which has a white coat.  Consequently, male chimeric mice with a high proportion 
of brown fur and therefore a high probability of transmitting the targeted allele to their 
offspring, were mated with wild-type C57BL/6 females (Figure 6.9).  Agouti mice with 
brown coats were produced when the targeted 129/SvEv ES cell genome successfully  
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populated the germ cells of the chimera. 
 
6.  Inactivation of the Functional Allele by Cre Recombinase 
 Figure 6.9 shows the mating strategy used to create ASKO mice.  First, agouti mice 
heterozygous for the targeted STAT3 gene (STAT3flox/+) were mated with transgenic mice 
expressing Cre recombinase under the control of the adipocyte specific aP2 promoter (aP2-
Cre  STAT3+/+, Jackson Laboratories, Bar Harbor, Maine).  A quarter of the offspring 
inherited both the targeted allele and the Cre-expressing transgene (aP2-Cre  STAT3flox/+).  
These mice were then intercrossed to yield six derivative strains:  (a) STAT3+/+ (WT), (b) 
STAT3flox/+ (WT), (c) STAT3flox/flox (WT), (d) STAT3+/+/Cre (WT), (e) STAT3flox/+/Cre 
(HZ), and (f) STAT3flox/flox/Cre (ASKO).  To assess the efficiency of Cre-mediated STAT3 
deletion, adipose tissue excised from experimental mice was screened by PCR (Figure 6.10). 
 
B.  PRIMARY PREADIPOCYTES 
1.  Isolation and Culture of Stromal-Vascular Cells  
 Subcutaneous WAT was aseptically removed from 20-week old male mice and 
stromal vascular cell cultures were established as previously described (169).  Briefly, 
inguinal WAT was excised from freshly killed ASKO mice and littermate controls.  After 
excision, adipose tissue was minced into small pieces, washed in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 1% bovine serum albumin (BSA), and 
centrifuged at 1000 x g for 10 minutes to remove blood cells.  Tissue was then decanted into 
DMEM containing 1.0 mg/ml type I collagenase and digested for 45 minutes at 37ºC with 
constant end-over-end inversion.  Following the digestion, adipose cells and stromal vascular 
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cells were separated by centrifugation at 500 x g for 10 minutes.  The stromal vascular cell 
pellet was then resuspended and cultured in DMEM containing 10% v/v FBS, 10 mg/ml 
streptomycin, 100 U/ml penicillin, and 1 mM pyruvate at 37°C in 5% CO2 air.   
  
 To induce differentiation, 2-day postconfluent preadipocytes were treated with Zen-
Bio Differentiation Medium (Zen-Bio, Raleigh, NC).  On day 3, the differentiation medium 
was replaced with Zen-Bio Adipocyte Maintenance Medium, which was changed every 
2 days thereafter until analysis on day 8.  To determine whether the primary preadipocytes 
differentiated into mature adipocytes, eight days after induction of differentiation cells were 
washed with PBS, fixed with 3.7% formaldehyde in PBS, and then stained with 0.5% Oil 
Red-O.  As shown in Figure 6.11, primary preadipocytes stimulated with differentiation 
medium efficiently differentiated into mature adipocytes.  No differences were observed 
between ASKO cells and littermate control cells. 
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D.  Knockout Allele 
Figure 6.1 - Targeting Strategy 
Schematic representation of (A) the STAT3 targeting vector, (B) the endogenous STAT3 
allele before (wild-type allele) and after (targeted allele) homologous recombination, (C) the 
targeted allele after FlpE recombination (functional allele), and (D) the functional allele after 
Cre-mediated deletion of exon 22 (knockout allele).                                                                             
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Figure 6.2 – The OSfrt-loxP Plasmid 
Schematic representation of the OSfrt-loxP plasmid. This plasmid contains several unique 
features including a positive selection marker (neo), a negative selection marker (TK), FRT 
sites flanking neo, a loxP site, and five unique restriction sites, SpeI, AgeI, XhoI, BamHI, 
and SalI.  The positive selection marker neo confer resistance to neomycin while the negative 
selection marker TK is sensitive to gancyclovir.  FlpE recombinase and Cre recombinase 
catalyze the site specific recombination of DNA between FRT sites and loxP sites 
respectively.   
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                                              Short Arm                     Long Arm                     Target Arm 
     
 
Figure 6.3 - Long Arm, Short Arm, Target Arm Amplification   
PCR analysis of 129/SvEv genomic DNA amplified utilizing the SAStatF and SAStatR 
primers, the LAStatF and LAStatR primers, and the E22StatR and E22StatR primers. 
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Figure 6.4 - The Assembled Targeting Vector      
(A) Schematic representation of the assembled targeting vector.  The long arm, spanning 
exon 21 of the STAT3 gene, was cloned into the OSfrt-loxP plasmid at the SpeI and AgeI 
restriction sites.  The short arm, spanning exons 23 and 24 of the STAT3 gene, was cloned 
into the OSfrt-loxP plasmid at the BamHI and SalI restriction sites.  The target arm, spanning 
exon 22 of the STAT3 gene and including a tyrosine residue necessary for STAT3 activation, 
was cloned into the OSfrt-loxP plasmid at the AgeI and XhoI restriction sites. 
(B)  A series of diagnostic digests were performed to confirm proper assembly of the 
targeting vector.  A SpeI/AgeI digest produced an 8.5kb fragment and a 3.3kb fragment (long 
arm).  A BamHI/SalI digest produced a 9.4kb fragment and a 2.4kb fragment (short arm).  
An AgeI/XhoI digest produced an 11.5kb fragment and a 339bp fragment (target arm).  A 
SpeI/AgeI/BamHI/SalI/XhoI digest produced a 4.6kb fragment, a 3.3kb fragment (long arm), 
a 2.4kb fragment (short arm), a 1.3kb fragment, and a 339bp fragment (target arm).
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Figure 6.5 - Assessment of Homologous Recombination Using PCR 
(A) Schematic representation of the STAT3 allele before (wild-type allele) and after (targeted 
allele) homologous recombination.  The position of the forward and reverse primers used for 
PCR analysis are shown by the arrows labeled F and R respectively.  The forward primer 
binds to the neo cassette and the reverse primer binds to a region outside of the targeting 
vector within the endogenous locus.  A 2.6kb PCR product was expected if a recombination 
event occurred at the STAT3 locus.  A PCR product was not expected if a recombination 
event did not occur.   
(B) PCR analysis of DNA prepared from 129/SvEv ES cells electroporated with the 
assembled targeting vector.   
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Figure 6.6 - Assessment of Homologous Recombination Using Southern Blot Analysis 
(A) Schematic representation of the STAT3 allele before (wild-type allele) and after (targeted 
allele) homologous recombination.  The position of the probe used for Southern blot analysis 
is shown by the line labeled Probe.  Following a BglII digest, a 7.0kb band was expected if a 
recombination event occurred at the STAT3 locus.  A 5.9kb band was expected if a 
recombination event did not occur. 
(B) Southern blot analysis of DNA isolated from ES cell clones carrying the desired 
homologous recombination event as identified by PCR.  DNA from clone 1 produced a 7.0kb 
band (targeted allele) and a 5.9kb band (wild-type allele).  Only a 5.9 (wild-type allele) was 
detected in clone 2.   
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Figure 6.7 – Screening for Neo Removal Using PCR 
(A) Schematic representation of a targeted STAT3 allele before (targeted allele) and after 
(functional allele) FlpE recombination.  The position of the forward and reverse primers used 
for PCR analysis are shown by the arrows labeled F and R respectively.  The forward primer 
binds to the loxP site and the reverse primer binds to a region outside of the targeting vector 
within the endogenous locus.  A 3.0kb PCR product was expected if neo was removed by 
FlpE recombinase.  A 4.2kb PCR product was expected if neo was not removed.   
(B) PCR analysis of DNA isolated from targeted ES cell clones electroporated with FlpE 
recombinase.   
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Figure 6.8 - Blastocyst Microinjection 
129/SvEv targeted clones not containing neo microinjected into C57BL/6 blastocysts. 
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Figure 6.9 – Mating Strategy 
Schematic representation of the mating strategy used to generate ASKO mice. 
(A) Chimeric mice (STAT3flox/+) were mated with wild-type mice (STAT3+/+).   
(B) Agouti mice heterozygous for the targeted STAT3 gene (STAT3flox/+) were mated with 
transgenic mice expressing Cre recombinase under the control of the adipocyte-specific aP2 
promoter (aP2-Cre).   
(C) Mice inheriting both the targeted allele and the Cre-expressing transgene (aP2-Cre  
STAT3flox/+) were intercrossed to yield six derivative strains.  Adipocyte-specific STAT3-/- 
mice (    ) were generated at a ratio of 3:16.  Adipocyte-specific STAT3+/- (    ) mice were 
generated at a ratio of 3:8.  Wild-type mice (    ) were generated at a ratio of 7:16. 
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Figure 5.10 – Assessment of STAT3 Recombination in Adipose Tissue 
(A) Schematic representation of the STAT3 allele before (functional allele) and after 
(knockout allele) recombination.  The position of the forward and reverse primers used for 
PCR analysis are shown by the arrows labeled F and R respectively.  The forward primer 
binds to the loxP site and the reverse primer binds to Exon 22.  A 336bp PCR product was 
expected if exon 22 was removed by the Cre recombinase.  A 682bp PCR product was 
expected if exon 22 was not removed.   
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Figure 6.11 – Lipid Accumulation in Primary Preadipocytes   
Eight days after induction of differentiation, ASKO cells were stained with Oil Red-O. 
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